ClinicalTrials.gg
CompletedNCT03622580Updated Jul 11, 2025Results posted

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)

A Phase 3 interventional study of Aflibercept and Faricimab in Diabetic Macular Edema, sponsored by Hoffmann-La Roche. Completed at 185 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-11.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
940
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing faricimab in Macular Edema — 1 open to participants now, 3 under way, none of them phase 3. faricimab · Macular Edema.

Enrollment
3rd of 13
940 · median 229
Started
2018
with 1 other
Phase 3
7 of 13
none open now
Registered
3rd of 13
by date
Lead sponsor
8 of 13
Hoffmann-La Roche

Among the 13 studies testing faricimab in Macular Edema, this one is the 3rd largest by enrollment, is one of 2 that started in 2018, is one of 7 in phase 3, and was the 3rd registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 13 studies testing faricimab in Macular Edema is open now. Recruiting first, the newest first:

About faricimab

faricimab: first FDA approval 2022 (VABYSMO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing faricimab in Macular Edema, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of diabetes mellitus (Type 1 or Type 2)
  • (HbA1c) of less than or equal to (≤) 10% within 2 months prior to Day 1
  • Macular thickening secondary to diabetic macular edema (DME) involving the center of the fovea
  • Decreased visual acuity attributable primarily to DME
  • Ability and willingness to undertake all scheduled visits and assessments
  • For women of : agreement to remain abstinent or use acceptable methods that result in a failure rate of \<1% per year during the treatment period and for at least 3 months after the final dose of study treatment

Exclusion criteria

Exclusion Criteria:

  • Currently untreated diabetes mellitus or previously untreated patients who initiated oral or injectable anti-diabetic medication within 3 months prior to Day 1
  • Uncontrolled blood pressure, defined as a systolic value greater than (>)180 millimeters of mercury (mmHg) and/or a diastolic value >100 mmHg while a patient is at rest
  • Currently pregnant or breastfeeding, or intend to become pregnant during the study
  • Treatment with panretinal photocoagulation or macular laser within 3 months prior to Day 1 to the study eye
  • Any intraocular or periocular treatment within the past 6 months prior to Day 1 to the study eye
  • Prior administration of IVT faricimab in either eye
  • Active intraocular or periocular infection or active intraocular inflammation in the study eye
  • Any current or history of ocular disease other than DME that may confound assessment of the macula or affect central vision in the study eye
  • Any current ocular condition which, in the opinion of the investigator, is currently causing or could be expected to contribute to irreversible vision loss due to a cause other than DME in the study eye
  • Other protocol-specified inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
940 participants (actual)

Study arms

  • Experimental
    A: Faricimab 6 mg Q8W

    Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.

    Drug: Faricimab · Procedure: Sham Procedure

  • Experimental
    B: Faricimab 6 mg PTI

    Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections once every 4 weeks (Q4W), 8 weeks (Q8W), 12 weeks (Q12W), or 16 weeks (Q16W) up to Week 96, followed by the final study visit at Week 100.

    Drug: Faricimab · Procedure: Sham Procedure

  • Active comparator
    C: Aflibercept 2 mg Q8W

    Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.

    Drug: Aflibercept · Procedure: Sham Procedure

Interventions

  • Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).

    Also known as: Eylea

  • Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.

    Also known as: VABYSMO™, RO6867461, RG7716

  • ProcedureSham Procedure

    The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable clinic visits to maintain masking among treatment arms.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded. 97.5% CI is a rounding of 97.52% CI.

    Time frame: From Baseline through Week 56

Secondary outcomes

  1. Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale at Week 52, ITT and Treatment-Naive Populations

    The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 97.5% confidence interval (CI) is a rounding of 97.52% CI.

    Time frame: Baseline and Week 52

  2. Change From Baseline in BCVA in the Study Eye Over Time, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded. 95% CI is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  3. Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population

    Best-Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline BCVA (continuous), baseline BCVA (\<64 vs. ≥64 letters), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  4. Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT Population

    BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, average of Weeks 48, 52, and 56

  5. Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  6. Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  7. Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  8. Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  9. Percentage of Participants Gaining ≥15, ≥10, ≥5, or ≥0 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, Treatment-Naive Population

    BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, average of Weeks 48, 52, and 56

  10. Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  11. Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  12. Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  13. Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  14. Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, average of Weeks 48, 52, and 56

  15. Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  16. Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  17. Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  18. Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, Treatment-Naive Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, average of Weeks 48, 52, and 56

  19. Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  20. Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  21. Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  22. Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

    BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, average of Weeks 48, 52, and 56

  23. Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  24. Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  25. Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

    BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥69 vs. \<69 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, average of Weeks 48, 52, and 56

  26. Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥69 vs. \<69 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  27. Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥69 vs. \<69 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  28. Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

    BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, average of Weeks 48, 52, and 56

  29. Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement invisual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  30. Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  31. Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population

    The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 16, 52, and 96

  32. Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population

    The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 16, 52, and 96

  33. Percentage of Participants With a ≥3-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population

    The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 16, 52, and 96

  34. Percentage of Participants With a ≥3-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population

    The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 16, 52, and 96

  35. Percentage of Participants With a ≥4-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population

    The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 16, 52, and 96

  36. Percentage of Participants With a ≥4-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population

    The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 16, 52, and 96

  37. Percentage of Participants Without Proliferative Diabetic Retinopathy (PDR) at Baseline Who Developed New PDR at Week 52, ITT and Treatment-Naive Populations

    The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). PDR was defined as an ETDRS DRSS score of ≥61 on the 7-field/4-wide field color fundus photographs assessment by a central reading center. The weighted percentages of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% CI is a rounding of 95.04% CI.

    Time frame: Baseline and Week 52

  38. Percentage of Participants Without High-Risk Proliferative Diabetic Retinopathy (PDR) at Baseline Who Developed High-Risk PDR at Week 52, ITT and Treatment-Naive Populations

    The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced PDR. High-risk PDR was defined as an ETDRS DRSS score of ≥71 on the 7-field/4-wide field color fundus photographs assessment by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% CI is a rounding of 95.04% CI.

    Time frame: Baseline and Week 52

  39. Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 52, ITT Population

    Time frame: Week 52

  40. Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 52, Treatment-Naive Population

    Time frame: Week 52

  41. Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 96, ITT Population

    Time frame: Week 96

  42. Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 96, Treatment-Naive Population

    Time frame: Week 96

  43. Percentage of Participants in the Faricimab 6 mg PTI Arm at Week 52 Who Achieved a Once Every 12-Weeks or 16-Weeks Treatment Interval Without an Interval Decrease Below Once Every 12 Weeks, ITT and Treatment-Naive Populations

    Time frame: From start of PTI (Week 12 or later) until Week 52

  44. Percentage of Participants in the Faricimab 6 mg PTI Arm at Week 96 Who Achieved a Once Every 12-Weeks or 16-Weeks Treatment Interval Without an Interval Decrease Below Once Every 12 Weeks, ITT and Treatment-Naive Populations

    Time frame: From start of PTI (Week 12 or later) until Week 96

  45. Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

    Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment (U.S. and Canada vs. the rest of the world; Asia and rest of the world regions were combined). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: From Baseline through Week 56

  46. Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population

    Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment (U.S. and Canada vs. the rest of the world; Asia and rest of the world regions were combined). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  47. Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population

    Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (\<64 vs. ≥64 letters), and region of enrollment (U.S. and Canada vs. the rest of the world; Asia and rest of the world regions were combined). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  48. Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

    Absence of diabetic macular edema was defined as achieving a central subfield thickness (CST) of \<325 microns in the study eye. CST was defined as the distance between the internal limiting membrane and Bruch's membrane. For each participant, an average CST value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Average of Weeks 48, 52, and 56

  49. Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population

    Absence of diabetic macular edema was defined as achieving a central subfield thickness of \<325 microns in the study eye. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  50. Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population

    Retinal dryness was defined as achieving a central subfield thickness (ILM-BM) of \<280 microns. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted estimates of the percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  51. Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye Over Time, ITT Population

    Intraretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world); Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 16, 48, 52, 56, 92, 96, and 100

  52. Percentage of Participants With Absence of Subretinal Fluid in the Study Eye Over Time, ITT Population

    Subretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world); Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 16, 48, 52, 56, 92, 96, and 100

  53. Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time, ITT Population

    Intraretinal fluid and subretinal fluid were measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world); Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 16, 48, 52, 56, 92, 96, and 100

  54. Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Composite Score Over Time, ITT Population

    The NEI VFQ-25 captures a patient's perception of vision-related functioning and quality of life. The core measure includes 25 items that comprise 11 vision-related subscales and one item on general health. The composite score ranges from 0 to 100, with higher scores, or a positive change from baseline, indicating better vision-related functioning. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline NEI VFQ-25 Composite Score (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% CI is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 24, 52, and 100

  55. Percentage of Participants With at Least One Adverse Event

    This analysis of adverse events (AEs) includes both ocular and non-ocular (systemic) AEs. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. AEs of special interest included the following: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law; Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation.

    Time frame: From first dose of study drug through end of study (up to 2 years)

  56. Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye

    This analysis of adverse events (AEs) only includes ocular AEs, which are categorized as having occurred either in the study eye or the fellow eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation.

    Time frame: From first dose of study drug through end of study (up to 2 years)

  57. Percentage of Participants With at Least One Non-Ocular Adverse Event

    This analysis of adverse events (AEs) only includes non-ocular (systemic) AEs. Investigators sought information on adverse events (AEs) at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. The non-ocular AE of special interest was: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

    Time frame: From first dose of study drug through end of study (up to 2 years)

  58. Plasma Concentration of Faricimab Over Time

    Faricimab concentration in plasma was determined using a validated immunoassay method.

    Time frame: Pre-dose on Day 1 (Baseline); Weeks 4, 28, 52, 76, and 100

  59. Percentage of Participants Who Test Positive for Treatment-Emergent Anti-Drug Antibodies Against Faricimab During the Study

    Anti-drug antibodies (ADAs) against fariciamb were detected in plasma using a validated bridging enzyme-linked immunosorbent assay (ELISA). The percentage of participants with treatment-emergent ADA-positive samples includes post-baseline evaluable participants with at least one treatment-induced (defined as having an ADA-negative sample or missing sample at baseline and any positive post-baseline sample) or treatment-boosted (defined as having an ADA-positive sample at baseline and any positive post-baseline sample with a titer that is equal to or greater than 4-fold baseline titer) ADA-positive sample during the study treatment period.

    Time frame: Baseline, Weeks 4, 28, 52, 76, and 100

07

Results

Posted Mar 22, 2022
Limitations and caveats
All secondary outcome measures were unpowered for statistical analysis, and the results should be interpreted with caution.

Participant flow

Participant flow — Overall Study
MilestoneA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Started315313312
Received at least one dose of study drug313313311
Completed up to week 56291289292
Completed263269260
Not completed524452
Withdrew: Death162113
Withdrew: Adverse event665
Withdrew: Withdrawal by subject12719
Withdrew: Lost to follow-up1299
Withdrew: Protocol violation101
Withdrew: Physician decision301
Withdrew: Pregnancy010
Withdrew: Lack of efficacy001
Withdrew: Other203

Outcome measures

PrimaryChange From Baseline in BCVA in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded. 97.5% CI is a rounding of 97.52% CI.

Time frame:
From Baseline through Week 56
Reported as:
Mean · ETDRS Letters
Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations
ETDRS LettersA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
ITT Population10.7 (9.4 to 12.0)11.6 (10.3 to 12.9)10.9 (9.6 to 12.2)
Treatment-Naive Population10.6 (9.1 to 12.1)11.4 (9.9 to 12.8)11.3 (9.8 to 12.8)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Adjusted mean difference: -0.2 · 97.5% CI -2.0 to 1.6The difference in adjusted means was calculated as Arm A: Faricimab 6 mg Q8W minus Arm C: Aflibercept 2 mg Q8W in the ITT Population.
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Adjusted mean difference: 0.7 · 97.5% CI -1.1 to 2.5The difference in adjusted means was calculated as Arm B: Faricimab 6 mg PTI minus Arm C: Aflibercept 2 mg Q8W in the ITT Population.
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Mixed Model for Repeated Measures · p = 0.4699 (Tested at an overall significance level of α = 0.0248.) · Adjusted mean difference: -0.7 · 97.5% CI -2.8 to 1.4The difference in adjusted means was calculated as Arm A: Faricimab 6 mg Q8W minus Arm C: Aflibercept 2 mg Q8W in the Treatment-Naive Population.
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Mixed Model for Repeated Measures · p = 0.9650 (Tested at an overall significance level of α = 0.0248.) · Adjusted mean difference: 0.0 · 97.5% CI -2.1 to 2.2The difference in adjusted means was calculated as Arm B: Faricimab 6 mg PTI minus Arm C: Aflibercept 2 mg Q8W in the Treatment-Naive Population.
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Mixed Model for Repeated Measures · p = 0.7967 (Tested at an overall significance level of α = 0.0248.) · Adjusted mean difference: -0.2 · 97.5% CI -2.0 to 1.6The difference in adjusted means was calculated as Arm A: Faricimab 6 mg Q8W minus Arm C: Aflibercept 2 mg Q8W in the ITT Population.
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Mixed Model for Repeated Measures · p = 0.3772 (Tested at an overall significance level of α = 0.0248.) · Adjusted mean difference: 0.7 · 97.5% CI -1.1 to 2.5The difference in adjusted means was calculated as Arm B: Faricimab 6 mg PTI minus Arm C: Aflibercept 2 mg Q8W in the ITT Population.
SecondaryPercentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale at Week 52, ITT and Treatment-Naive Populations

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 97.5% confidence interval (CI) is a rounding of 97.52% CI.

Time frame:
Baseline and Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale at Week 52, ITT and Treatment-Naive Populations
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
ITT Population46.0 (38.8 to 53.1)42.5 (35.5 to 49.5)35.8 (29.1 to 42.5)
Treatment-Naive Population49.7 (41.2 to 58.2)47.6 (39.5 to 55.8)42.5 (34.4 to 50.6)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 10.2 · 97.5% CI 0.3 to 20.0
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 6.1 · 97.5% CI -3.6 to 15.8
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Cochran-Mantel-Haenszel · p = 0.1761 (Tested at an overall significance level of α = 0.0248.) · Difference in cmh weighted percentage: 7.2 · 97.5% CI -4.6 to 18.9
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Cochran-Mantel-Haenszel · p = 0.3539 (Tested at an overall significance level of α = 0.0248.) · Difference in cmh weighted percentage: 4.8 · 97.5% CI -6.7 to 16.3
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Cochran-Mantel-Haenszel · p = 0.0237 (Tested at an overall significance level of α = 0.0248.) · Difference in cmh weighted percentage: 10.2 · 97.5% CI 0.3 to 20.0
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Cochran-Mantel-Haenszel · p = 0.1677 (Tested at an overall significance level of α = 0.0248.) · Difference in cmh weighted percentage: 6.1 · 97.5% CI -3.6 to 15.8
SecondaryChange From Baseline in BCVA in the Study Eye Over Time, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded. 95% CI is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Mean · ETDRS Letters
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population
ETDRS LettersA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 45.5 (4.8 to 6.3)6.7 (6.0 to 7.4)6.5 (5.8 to 7.2)
Week 87.2 (6.4 to 7.9)8.2 (7.4 to 9.0)8.1 (7.3 to 8.8)
Week 128.2 (7.4 to 9.0)9.2 (8.4 to 10.0)9.1 (8.3 to 9.9)
Week 169.1 (8.2 to 9.9)10.0 (9.2 to 10.8)9.7 (8.8 to 10.5)
Week 209.6 (8.7 to 10.5)9.9 (9.0 to 10.8)9.8 (8.9 to 10.7)
Week 2410.2 (9.3 to 11.1)11.3 (10.4 to 12.2)9.4 (8.5 to 10.3)
Week 289.5 (8.6 to 10.5)11.0 (10.0 to 11.9)10.5 (9.6 to 11.5)
Week 3210.2 (9.2 to 11.2)10.9 (9.9 to 11.9)10.2 (9.2 to 11.2)
Week 3610.1 (9.1 to 11.1)11.7 (10.7 to 12.8)10.4 (9.4 to 11.4)
Week 4010.2 (9.1 to 11.2)11.4 (10.3 to 12.5)10.3 (9.2 to 11.4)
Week 449.9 (8.8 to 11.0)11.4 (10.3 to 12.5)10.7 (9.6 to 11.9)
Week 4810.5 (9.4 to 11.6)11.4 (10.3 to 12.5)10.8 (9.7 to 11.9)
Week 529.9 (8.7 to 11.1)11.0 (9.8 to 12.2)10.9 (9.7 to 12.2)
Week 5610.8 (9.7 to 12.0)11.6 (10.4 to 12.8)10.6 (9.4 to 11.8)
Week 6010.3 (9.1 to 11.5)12.0 (10.8 to 13.1)11.3 (10.1 to 12.5)
Week 6410.7 (9.5 to 12.0)11.5 (10.3 to 12.7)10.8 (9.6 to 12.0)
Week 6810.2 (8.9 to 11.5)11.4 (10.1 to 12.6)11.3 (10.0 to 12.5)
Week 7210.4 (9.1 to 11.7)11.3 (10.0 to 12.6)10.7 (9.4 to 12.0)
Week 7610.2 (8.8 to 11.6)11.5 (10.1 to 12.9)11.0 (9.6 to 12.4)
Week 8010.9 (9.5 to 12.2)11.1 (9.8 to 12.4)10.9 (9.6 to 12.2)
Week 849.9 (8.6 to 11.2)11.5 (10.2 to 12.8)11.8 (10.5 to 13.1)
Week 889.8 (8.4 to 11.2)10.9 (9.5 to 12.3)11.0 (9.6 to 12.4)
Week 9210.5 (9.1 to 11.9)11.2 (9.9 to 12.6)11.5 (10.1 to 12.9)
Week 9611.1 (9.7 to 12.6)10.6 (9.2 to 12.0)11.1 (9.7 to 12.5)
Week 10010.5 (9.1 to 12.0)10.4 (9.0 to 11.8)11.6 (10.1 to 13.1)
SecondaryChange From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population

Best-Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline BCVA (continuous), baseline BCVA (\<64 vs. ≥64 letters), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Mean · ETDRS Letters
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population
ETDRS LettersA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 45.8 (5.0 to 6.7)6.8 (6.0 to 7.6)6.9 (6.1 to 7.7)
Week 87.2 (6.3 to 8.1)8.3 (7.4 to 9.2)8.7 (7.8 to 9.5)
Week 128.5 (7.6 to 9.4)9.3 (8.4 to 10.2)9.6 (8.7 to 10.5)
Week 169.3 (8.4 to 10.3)10.0 (9.1 to 10.9)10.1 (9.2 to 11.1)
Week 209.7 (8.7 to 10.8)9.7 (8.6 to 10.7)10.3 (9.3 to 11.4)
Week 2410.5 (9.4 to 11.5)11.2 (10.2 to 12.2)9.8 (8.7 to 10.8)
Week 289.6 (8.5 to 10.7)11.0 (9.9 to 12.1)11.0 (9.9 to 12.1)
Week 3210.3 (9.1 to 11.5)10.9 (9.8 to 12.1)10.6 (9.5 to 11.8)
Week 3610.3 (9.1 to 11.6)11.9 (10.7 to 13.1)10.6 (9.4 to 11.8)
Week 4010.0 (8.7 to 11.3)11.4 (10.1 to 12.7)10.7 (9.4 to 12.1)
Week 4410.1 (8.8 to 11.4)11.4 (10.1 to 12.7)11.3 (10.0 to 12.6)
Week 4810.3 (9.0 to 11.7)11.0 (9.7 to 12.4)11.2 (9.8 to 12.5)
Week 529.6 (8.2 to 11.1)10.7 (9.3 to 12.2)11.3 (9.9 to 12.8)
Week 5610.9 (9.5 to 12.3)11.5 (10.1 to 12.8)11.0 (9.6 to 12.4)
Week 6010.1 (8.7 to 11.6)12.0 (10.6 to 13.4)11.6 (10.2 to 13.0)
Week 6410.6 (9.1 to 12.1)11.5 (10.0 to 13.0)11.0 (9.5 to 12.4)
Week 6810.3 (8.8 to 11.8)11.3 (9.8 to 12.8)11.4 (9.9 to 12.9)
Week 7210.2 (8.6 to 11.7)11.3 (9.8 to 12.8)10.8 (9.3 to 12.4)
Week 769.9 (8.2 to 11.6)11.4 (9.7 to 13.0)10.8 (9.2 to 12.5)
Week 8010.6 (9.0 to 12.2)11.0 (9.4 to 12.6)11.1 (9.6 to 12.7)
Week 849.6 (8.0 to 11.1)11.6 (10.0 to 13.1)11.9 (10.3 to 13.4)
Week 889.4 (7.7 to 11.1)10.8 (9.1 to 12.5)10.9 (9.2 to 12.6)
Week 9210.1 (8.4 to 11.7)11.2 (9.5 to 12.8)11.6 (10.0 to 13.3)
Week 9611.1 (9.4 to 12.8)10.5 (8.9 to 12.1)11.4 (9.7 to 13.0)
Week 10010.5 (8.8 to 12.3)10.5 (8.8 to 12.1)11.7 (10.0 to 13.4)
SecondaryPercentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT Population

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, average of Weeks 48, 52, and 56
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Gaining ≥15 Letters29.2 (23.9 to 34.5)35.5 (30.1 to 40.9)31.8 (26.6 to 37.0)
Gaining ≥10 Letters57.2 (51.3 to 63.1)58.3 (52.6 to 64.0)57.6 (51.8 to 63.4)
Gaining ≥5 Letters78.9 (74.1 to 83.8)79.6 (74.9 to 84.3)81.4 (76.9 to 86.0)
Gaining ≥0 Letters91.5 (88.1 to 94.8)94.5 (91.8 to 97.2)91.4 (88.1 to 94.6)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -2.6 · 95% CI -10.0 to 4.9
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 3.5 · 95% CI -4.0 to 11.1
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -0.4 · 95% CI -8.6 to 7.9
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.7 · 95% CI -7.4 to 8.8
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -2.5 · 95% CI -9.1 to 4.1
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -2.0 · 95% CI -8.5 to 4.5
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.1 · 95% CI -4.6 to 4.8
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 3.3 · 95% CI -1.0 to 7.5
SecondaryPercentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 47.7 (4.8 to 10.7)13.0 (9.4 to 16.6)11.4 (8.0 to 14.9)
Week 813.4 (9.6 to 17.1)18.8 (14.8 to 22.9)16.7 (12.7 to 20.7)
Week 1214.9 (11.0 to 18.9)23.1 (18.6 to 27.5)22.1 (17.6 to 26.5)
Week 1620.4 (15.9 to 24.9)27.8 (22.9 to 32.7)22.2 (17.7 to 26.8)
Week 2025.6 (20.8 to 30.5)28.4 (23.4 to 33.4)24.0 (19.4 to 28.6)
Week 2426.8 (21.8 to 31.8)34.2 (29.0 to 39.3)25.7 (21.0 to 30.5)
Week 2823.5 (18.6 to 28.4)31.2 (26.2 to 36.3)29.2 (24.3 to 34.2)
Week 3228.5 (23.1 to 33.8)36.2 (30.7 to 41.7)25.8 (21.0 to 30.7)
Week 3624.4 (19.3 to 29.5)40.2 (34.6 to 45.8)32.5 (27.1 to 37.9)
Week 4029.7 (24.3 to 35.1)37.1 (31.6 to 42.7)30.3 (24.9 to 35.6)
Week 4429.2 (23.8 to 34.6)37.1 (31.7 to 42.6)34.9 (29.4 to 40.4)
Week 4831.7 (26.1 to 37.2)39.6 (33.9 to 45.3)34.0 (28.7 to 39.3)
Week 5231.2 (25.7 to 36.8)37.2 (31.7 to 42.7)36.0 (30.3 to 41.6)
Week 5638.1 (32.3 to 43.9)38.4 (32.7 to 44.0)31.5 (26.1 to 36.9)
Week 6034.4 (28.8 to 40.0)41.3 (35.5 to 47.1)35.9 (30.3 to 41.4)
Week 6437.5 (31.7 to 43.4)41.4 (35.8 to 47.1)34.8 (29.1 to 40.5)
Week 6837.1 (31.4 to 42.9)43.7 (37.9 to 49.6)37.1 (31.4 to 42.8)
Week 7234.8 (29.1 to 40.6)38.2 (32.6 to 43.8)35.2 (29.5 to 41.0)
Week 7636.6 (30.7 to 42.6)44.1 (38.4 to 49.9)37.2 (31.3 to 43.1)
Week 8039.3 (33.4 to 45.3)42.1 (36.5 to 47.8)36.9 (31.1 to 42.6)
Week 8440.6 (34.5 to 46.6)41.5 (35.8 to 47.2)38.8 (32.9 to 44.6)
Week 8839.2 (33.2 to 45.2)39.8 (34.2 to 45.4)35.9 (30.1 to 41.6)
Week 9239.7 (33.8 to 45.7)41.0 (35.3 to 46.6)38.8 (33.0 to 44.7)
Week 9641.3 (35.1 to 47.4)40.2 (34.5 to 45.8)38.8 (32.9 to 44.7)
Week 10040.2 (34.2 to 46.1)40.3 (34.7 to 46.0)40.9 (34.9 to 46.9)
SecondaryPercentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 423.9 (19.2 to 28.6)31.1 (26.2 to 36.1)27.1 (22.2 to 32.0)
Week 830.8 (25.7 to 35.9)37.1 (31.8 to 42.3)41.0 (35.6 to 46.4)
Week 1235.5 (30.2 to 40.8)47.5 (42.0 to 53.0)46.2 (40.7 to 51.7)
Week 1643.7 (38.0 to 49.3)48.4 (42.8 to 54.0)49.7 (44.1 to 55.3)
Week 2045.6 (40.0 to 51.3)53.1 (47.6 to 58.6)50.3 (44.7 to 56.0)
Week 2455.6 (50.0 to 61.2)58.6 (53.2 to 64.1)48.2 (42.6 to 53.9)
Week 2855.6 (49.9 to 61.3)57.0 (51.4 to 62.6)57.2 (51.6 to 62.9)
Week 3256.7 (50.9 to 62.6)58.5 (52.8 to 64.2)53.1 (47.3 to 58.8)
Week 3655.6 (49.7 to 61.5)65.5 (60.0 to 71.1)55.7 (49.9 to 61.6)
Week 4055.7 (49.8 to 61.5)60.0 (54.2 to 65.8)53.2 (47.2 to 59.2)
Week 4455.1 (49.3 to 61.0)60.5 (54.7 to 66.2)57.2 (51.3 to 63.2)
Week 4857.0 (51.0 to 62.9)60.2 (54.5 to 65.9)61.7 (55.9 to 67.4)
Week 5259.9 (54.0 to 65.8)59.5 (53.8 to 65.2)60.2 (54.3 to 66.2)
Week 5663.5 (57.7 to 69.4)62.6 (56.9 to 68.3)59.0 (53.0 to 64.9)
Week 6059.4 (53.5 to 65.2)62.6 (56.9 to 68.3)60.7 (54.9 to 66.5)
Week 6464.9 (59.2 to 70.7)60.0 (54.3 to 65.7)59.6 (53.8 to 65.5)
Week 6860.1 (54.2 to 66.0)58.9 (53.1 to 64.7)59.4 (53.5 to 65.4)
Week 7261.2 (55.2 to 67.1)61.0 (55.2 to 66.8)56.8 (50.7 to 62.9)
Week 7660.1 (54.1 to 66.2)67.8 (62.3 to 73.3)64.2 (58.3 to 70.0)
Week 8064.0 (58.1 to 70.0)61.7 (56.1 to 67.4)60.5 (54.5 to 66.4)
Week 8461.0 (55.0 to 67.0)64.4 (58.8 to 70.1)64.4 (58.6 to 70.2)
Week 8859.6 (53.5 to 65.7)59.8 (54.0 to 65.7)62.7 (56.9 to 68.5)
Week 9263.2 (57.3 to 69.1)63.3 (57.6 to 69.0)64.6 (58.7 to 70.4)
Week 9660.3 (54.1 to 66.4)59.7 (53.9 to 65.5)62.5 (56.5 to 68.6)
Week 10063.0 (57.3 to 68.8)60.5 (54.8 to 66.2)66.0 (60.1 to 71.8)
SecondaryPercentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 453.6 (48.1 to 59.1)62.6 (57.3 to 67.9)61.1 (55.7 to 66.5)
Week 864.7 (59.4 to 70.0)71.1 (66.1 to 76.0)67.6 (62.4 to 72.8)
Week 1271.9 (66.9 to 76.9)74.3 (69.4 to 79.2)75.4 (70.6 to 80.3)
Week 1674.9 (70.0 to 79.9)81.4 (77.0 to 85.8)77.5 (72.7 to 82.2)
Week 2078.2 (73.6 to 82.9)78.4 (73.7 to 83.1)76.4 (71.6 to 81.1)
Week 2480.5 (76.0 to 85.0)83.3 (79.0 to 87.5)71.0 (65.8 to 76.1)
Week 2877.4 (72.5 to 82.2)81.0 (76.6 to 85.5)79.1 (74.4 to 83.8)
Week 3279.4 (74.6 to 84.3)77.1 (72.2 to 82.0)81.3 (76.8 to 85.8)
Week 3679.2 (74.4 to 84.1)82.6 (78.2 to 87.1)78.3 (73.5 to 83.1)
Week 4076.3 (71.3 to 81.3)84.3 (80.0 to 88.6)77.1 (72.0 to 82.2)
Week 4480.7 (75.9 to 85.4)81.9 (77.3 to 86.4)77.9 (73.0 to 82.7)
Week 4879.2 (74.4 to 84.1)82.0 (77.5 to 86.6)79.3 (74.4 to 84.1)
Week 5278.4 (73.5 to 83.4)78.4 (73.5 to 83.2)81.2 (76.4 to 85.9)
Week 5683.0 (78.5 to 87.6)81.3 (76.6 to 86.0)81.4 (76.7 to 86.1)
Week 6080.4 (75.7 to 85.1)81.3 (76.7 to 85.9)81.4 (76.8 to 86.1)
Week 6480.2 (75.4 to 85.1)80.6 (75.9 to 85.2)79.7 (74.9 to 84.5)
Week 6879.1 (74.1 to 84.0)78.9 (74.0 to 83.8)79.1 (74.2 to 84.0)
Week 7279.7 (74.8 to 84.6)78.1 (73.2 to 83.0)80.9 (76.1 to 85.7)
Week 7679.9 (74.9 to 84.8)78.9 (74.0 to 83.8)82.9 (78.3 to 87.5)
Week 8081.0 (76.1 to 85.9)80.3 (75.5 to 85.0)78.3 (73.2 to 83.4)
Week 8477.1 (71.9 to 82.3)82.0 (77.5 to 86.5)82.6 (77.9 to 87.2)
Week 8879.3 (74.2 to 84.3)80.5 (75.8 to 85.2)80.5 (75.6 to 85.5)
Week 9281.4 (76.6 to 86.3)82.1 (77.5 to 86.7)83.2 (78.6 to 87.7)
Week 9682.6 (77.8 to 87.3)77.4 (72.5 to 82.4)81.2 (76.3 to 86.0)
Week 10081.1 (76.3 to 85.9)77.0 (71.9 to 82.0)85.2 (80.9 to 89.6)
SecondaryPercentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 486.1 (82.3 to 90.0)90.8 (87.7 to 94.0)88.9 (85.4 to 92.3)
Week 889.7 (86.4 to 93.0)91.9 (88.8 to 94.9)91.1 (87.9 to 94.2)
Week 1292.5 (89.6 to 95.4)94.7 (92.2 to 97.2)92.7 (89.8 to 95.6)
Week 1691.2 (88.0 to 94.4)94.9 (92.4 to 97.4)93.7 (90.9 to 96.4)
Week 2093.9 (91.2 to 96.6)93.1 (90.2 to 96.0)92.2 (89.2 to 95.2)
Week 2493.1 (90.2 to 96.0)93.8 (91.0 to 96.5)89.9 (86.5 to 93.3)
Week 2890.4 (87.0 to 93.8)94.1 (91.4 to 96.8)91.5 (88.3 to 94.6)
Week 3292.1 (88.9 to 95.3)95.1 (92.6 to 97.7)91.3 (88.0 to 94.6)
Week 3692.1 (88.9 to 95.3)93.2 (90.2 to 96.2)90.4 (87.0 to 93.9)
Week 4090.9 (87.5 to 94.3)94.0 (91.1 to 96.8)93.2 (90.2 to 96.2)
Week 4491.0 (87.6 to 94.4)94.5 (91.8 to 97.2)91.0 (87.6 to 94.4)
Week 4895.2 (92.6 to 97.7)93.7 (90.8 to 96.5)91.3 (88.0 to 94.6)
Week 5289.8 (86.1 to 93.4)91.3 (88.0 to 94.7)91.0 (87.5 to 94.5)
Week 5691.4 (88.0 to 94.8)93.9 (91.0 to 96.7)90.6 (87.1 to 94.2)
Week 6089.5 (85.9 to 93.2)93.5 (90.5 to 96.4)92.8 (89.7 to 95.9)
Week 6491.3 (87.9 to 94.7)92.7 (89.6 to 95.8)92.0 (88.7 to 95.2)
Week 6892.1 (88.8 to 95.4)92.9 (89.8 to 96.0)91.9 (88.6 to 95.2)
Week 7288.5 (84.6 to 92.5)91.9 (88.7 to 95.2)90.0 (86.3 to 93.7)
Week 7687.8 (83.8 to 91.9)91.2 (87.8 to 94.7)92.5 (89.4 to 95.7)
Week 8089.2 (85.4 to 93.0)91.5 (88.1 to 94.9)89.6 (85.9 to 93.4)
Week 8487.1 (82.9 to 91.2)92.4 (89.2 to 95.6)93.5 (90.5 to 96.5)
Week 8887.3 (83.2 to 91.4)90.3 (86.7 to 93.8)89.9 (86.1 to 93.7)
Week 9289.4 (85.5 to 93.2)91.1 (87.6 to 94.6)90.8 (87.3 to 94.3)
Week 9690.7 (87.0 to 94.4)88.9 (85.1 to 92.6)90.5 (86.8 to 94.2)
Week 10088.3 (84.3 to 92.3)86.8 (82.7 to 90.9)92.0 (88.7 to 95.4)
SecondaryPercentage of Participants Gaining ≥15, ≥10, ≥5, or ≥0 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, Treatment-Naive Population

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, average of Weeks 48, 52, and 56
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥15, ≥10, ≥5, or ≥0 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Gaining ≥15 Letters28.6 (22.3 to 34.8)35.5 (29.3 to 41.7)33.8 (27.7 to 39.9)
Gaining ≥10 Letters57.5 (50.7 to 64.4)59.6 (53.2 to 65.9)57.5 (50.9 to 64.1)
Gaining ≥5 Letters80.0 (74.4 to 85.5)77.2 (71.6 to 82.8)84.5 (79.6 to 89.3)
Gaining ≥0 Letters91.5 (87.6 to 95.3)93.5 (90.2 to 96.8)91.6 (87.9 to 95.3)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -5.2 · 95% CI -14.0 to 3.5
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 1.7 · 95% CI -7.0 to 10.3
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.0 · 95% CI -9.5 to 9.5
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 2.1 · 95% CI -7.1 to 11.3
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -4.5 · 95% CI -11.9 to 2.9
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -7.2 · 95% CI -14.6 to 0.2
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -0.2 · 95% CI -5.5 to 5.2
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 2.0 · 95% CI -3.0 to 7.0
SecondaryPercentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 48.9 (5.3 to 12.5)14.9 (10.6 to 19.3)12.7 (8.6 to 16.9)
Week 814.3 (9.9 to 18.8)19.2 (14.6 to 23.8)17.8 (13.1 to 22.6)
Week 1215.7 (11.1 to 20.3)22.2 (17.2 to 27.1)24.2 (19.0 to 29.5)
Week 1621.3 (16.0 to 26.6)28.2 (22.6 to 33.8)24.0 (18.6 to 29.3)
Week 2026.5 (20.8 to 32.2)27.7 (22.2 to 33.3)26.2 (20.7 to 31.6)
Week 2427.1 (21.3 to 32.9)34.3 (28.4 to 40.2)27.5 (22.0 to 33.1)
Week 2821.5 (16.0 to 27.0)30.7 (25.0 to 36.4)32.8 (26.8 to 38.7)
Week 3227.2 (21.0 to 33.5)37.5 (31.2 to 43.8)29.5 (23.6 to 35.4)
Week 3623.5 (17.6 to 29.5)41.9 (35.5 to 48.2)34.9 (28.6 to 41.2)
Week 4027.6 (21.5 to 33.8)37.7 (31.2 to 44.1)33.5 (27.0 to 39.9)
Week 4427.2 (21.1 to 33.4)39.7 (33.3 to 46.0)37.0 (30.6 to 43.4)
Week 4832.5 (26.0 to 39.1)39.6 (33.1 to 46.0)36.3 (30.1 to 42.5)
Week 5230.7 (24.3 to 37.1)35.9 (29.6 to 42.1)37.4 (30.9 to 43.9)
Week 5637.7 (31.0 to 44.5)38.8 (32.3 to 45.2)34.3 (27.9 to 40.8)
Week 6033.1 (26.6 to 39.6)42.2 (35.6 to 48.9)38.9 (32.4 to 45.5)
Week 6437.9 (31.1 to 44.7)43.5 (37.0 to 50.0)36.0 (29.5 to 42.6)
Week 6837.4 (30.7 to 44.2)45.4 (38.7 to 52.1)39.0 (32.4 to 45.5)
Week 7235.6 (28.8 to 42.4)39.6 (33.1 to 46.0)36.6 (29.8 to 43.3)
Week 7637.6 (30.6 to 44.6)45.3 (38.8 to 51.8)37.2 (30.5 to 43.9)
Week 8039.7 (32.7 to 46.8)43.2 (36.8 to 49.7)40.5 (33.6 to 47.3)
Week 8440.7 (33.7 to 47.8)43.2 (36.8 to 49.7)41.2 (34.3 to 48.1)
Week 8839.1 (32.1 to 46.2)40.7 (34.4 to 47.1)38.0 (31.2 to 44.8)
Week 9240.2 (33.2 to 47.3)42.1 (35.7 to 48.5)40.4 (33.6 to 47.3)
Week 9642.9 (35.6 to 50.2)41.2 (34.9 to 47.6)40.1 (33.2 to 47.0)
Week 10041.7 (34.6 to 48.7)42.5 (36.1 to 48.9)41.2 (34.3 to 48.1)
SecondaryPercentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 425.2 (19.7 to 30.7)32.0 (26.3 to 37.7)29.2 (23.5 to 35.0)
Week 831.1 (25.2 to 37.1)37.2 (31.3 to 43.1)43.9 (37.7 to 50.2)
Week 1236.9 (30.8 to 43.1)46.5 (40.3 to 52.6)48.9 (42.6 to 55.2)
Week 1643.8 (37.3 to 50.3)47.8 (41.4 to 54.1)49.8 (43.5 to 56.2)
Week 2044.9 (38.4 to 51.4)53.7 (47.5 to 59.9)51.5 (45.1 to 57.9)
Week 2457.6 (51.1 to 64.1)57.9 (51.7 to 64.2)49.9 (43.5 to 56.3)
Week 2855.3 (48.6 to 61.9)56.6 (50.3 to 62.9)57.4 (50.8 to 63.9)
Week 3259.0 (52.2 to 65.9)59.6 (53.1 to 66.0)53.1 (46.5 to 59.7)
Week 3659.0 (52.1 to 65.9)66.3 (60.0 to 72.5)55.8 (49.1 to 62.5)
Week 4055.5 (48.7 to 62.4)59.7 (53.1 to 66.4)54.5 (47.7 to 61.4)
Week 4455.0 (48.1 to 61.9)59.2 (52.7 to 65.7)58.1 (51.3 to 64.8)
Week 4857.1 (50.2 to 64.0)58.5 (52.0 to 65.0)62.6 (56.0 to 69.2)
Week 5260.0 (53.1 to 66.8)58.8 (52.2 to 65.3)61.0 (54.2 to 67.8)
Week 5665.0 (58.3 to 71.7)62.9 (56.5 to 69.3)60.1 (53.4 to 66.8)
Week 6061.5 (54.7 to 68.2)63.4 (56.9 to 69.9)61.3 (54.5 to 68.0)
Week 6467.7 (61.1 to 74.3)59.8 (53.3 to 66.2)59.7 (53.0 to 66.4)
Week 6864.1 (57.4 to 70.8)60.7 (54.2 to 67.2)60.6 (53.9 to 67.3)
Week 7262.6 (55.8 to 69.5)62.5 (56.0 to 69.0)56.7 (49.8 to 63.7)
Week 7661.8 (54.8 to 68.9)66.8 (60.5 to 73.0)66.2 (59.6 to 72.9)
Week 8066.7 (59.8 to 73.5)62.4 (56.0 to 68.8)62.8 (56.0 to 69.6)
Week 8463.2 (56.3 to 70.1)65.3 (59.0 to 71.6)67.1 (60.5 to 73.6)
Week 8860.2 (53.2 to 67.3)60.9 (54.3 to 67.6)61.9 (55.1 to 68.7)
Week 9263.2 (56.2 to 70.2)65.1 (58.7 to 71.5)65.0 (58.2 to 71.7)
Week 9658.8 (51.5 to 66.0)60.6 (54.0 to 67.1)63.8 (56.9 to 70.6)
Week 10064.0 (57.3 to 70.7)62.4 (56.0 to 68.8)64.8 (58.0 to 71.6)
SecondaryPercentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 453.8 (47.5 to 60.2)63.1 (57.1 to 69.1)62.8 (56.7 to 68.9)
Week 863.4 (57.2 to 69.6)70.5 (64.8 to 76.2)70.4 (64.6 to 76.2)
Week 1272.7 (66.9 to 78.4)75.4 (69.9 to 80.8)77.0 (71.6 to 82.4)
Week 1675.6 (70.0 to 81.3)81.3 (76.3 to 86.3)79.3 (74.1 to 84.5)
Week 2079.0 (73.6 to 84.3)79.3 (74.0 to 84.6)78.2 (72.9 to 83.5)
Week 2481.7 (76.6 to 86.8)82.9 (78.1 to 87.7)71.4 (65.5 to 77.2)
Week 2876.9 (71.2 to 82.5)81.7 (76.6 to 86.7)80.0 (74.8 to 85.3)
Week 3280.0 (74.4 to 85.6)77.6 (72.0 to 83.1)83.7 (78.8 to 88.7)
Week 3680.5 (74.9 to 86.1)82.9 (77.9 to 88.0)79.6 (74.1 to 85.1)
Week 4077.1 (71.3 to 82.8)85.3 (80.5 to 90.1)80.0 (74.5 to 85.6)
Week 4481.4 (76.0 to 86.8)82.5 (77.4 to 87.6)80.8 (75.4 to 86.2)
Week 4879.5 (73.8 to 85.2)80.0 (74.6 to 85.4)80.8 (75.4 to 86.2)
Week 5278.7 (72.9 to 84.4)75.3 (69.5 to 81.1)82.3 (77.1 to 87.6)
Week 5684.0 (78.9 to 89.2)81.2 (75.9 to 86.4)81.9 (76.6 to 87.1)
Week 6081.0 (75.5 to 86.4)80.5 (75.2 to 85.8)80.0 (74.5 to 85.5)
Week 6480.7 (75.1 to 86.3)80.2 (74.9 to 85.6)80.3 (74.8 to 85.7)
Week 6882.0 (76.5 to 87.5)78.3 (72.6 to 83.9)79.7 (74.1 to 85.2)
Week 7281.5 (76.0 to 87.0)77.3 (71.6 to 82.9)80.9 (75.4 to 86.5)
Week 7679.5 (73.7 to 85.4)78.0 (72.4 to 83.6)83.8 (78.6 to 88.9)
Week 8082.0 (76.3 to 87.7)80.5 (75.2 to 85.8)80.0 (74.3 to 85.7)
Week 8478.6 (72.6 to 84.6)83.0 (78.0 to 87.9)81.8 (76.4 to 87.3)
Week 8877.9 (71.8 to 83.9)80.7 (75.4 to 86.1)80.6 (74.9 to 86.2)
Week 9280.5 (74.8 to 86.3)82.1 (76.8 to 87.3)82.5 (77.2 to 87.9)
Week 9682.7 (77.1 to 88.3)76.9 (71.2 to 82.5)82.4 (76.9 to 87.8)
Week 10080.0 (74.3 to 85.8)78.2 (72.6 to 83.9)85.7 (80.8 to 90.7)
SecondaryPercentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 486.3 (81.9 to 90.7)90.9 (87.3 to 94.5)90.2 (86.5 to 94.0)
Week 891.4 (87.8 to 95.0)93.3 (90.2 to 96.5)93.1 (89.9 to 96.4)
Week 1293.5 (90.4 to 96.6)96.2 (93.7 to 98.6)92.8 (89.4 to 96.1)
Week 1691.5 (87.8 to 95.1)94.7 (91.9 to 97.6)94.5 (91.6 to 97.4)
Week 2094.2 (91.2 to 97.2)92.5 (89.1 to 95.9)92.1 (88.6 to 95.6)
Week 2494.0 (90.9 to 97.1)93.4 (90.2 to 96.6)89.0 (85.0 to 93.1)
Week 2890.9 (87.0 to 94.8)94.2 (91.1 to 97.2)92.6 (89.1 to 96.1)
Week 3292.3 (88.5 to 96.0)94.2 (91.0 to 97.3)91.4 (87.7 to 95.2)
Week 3693.1 (89.5 to 96.7)93.7 (90.4 to 97.0)89.4 (85.2 to 93.6)
Week 4091.0 (87.0 to 94.9)93.6 (90.3 to 97.0)92.5 (88.9 to 96.2)
Week 4491.8 (88.0 to 95.6)93.4 (90.0 to 96.7)91.6 (87.8 to 95.4)
Week 4895.5 (92.6 to 98.4)91.9 (88.2 to 95.6)93.1 (89.7 to 96.6)
Week 5289.8 (85.6 to 94.0)89.5 (85.4 to 93.6)90.9 (87.0 to 94.9)
Week 5691.7 (87.8 to 95.6)92.7 (89.2 to 96.3)90.9 (86.9 to 94.9)
Week 6089.9 (85.7 to 94.1)93.5 (90.1 to 96.9)91.9 (88.2 to 95.7)
Week 6492.0 (88.1 to 95.9)92.6 (89.1 to 96.1)92.4 (88.7 to 96.1)
Week 6892.0 (88.1 to 95.8)93.4 (90.0 to 96.8)91.8 (88.0 to 95.6)
Week 7288.7 (84.1 to 93.2)92.0 (88.4 to 95.6)89.3 (84.9 to 93.7)
Week 7686.8 (81.8 to 91.7)90.8 (86.8 to 94.8)91.6 (87.8 to 95.5)
Week 8089.5 (85.0 to 94.0)90.7 (86.7 to 94.7)90.1 (85.8 to 94.3)
Week 8487.4 (82.6 to 92.3)92.2 (88.5 to 95.8)92.5 (88.9 to 96.1)
Week 8885.6 (80.4 to 90.7)88.8 (84.5 to 93.2)89.2 (84.7 to 93.7)
Week 9288.8 (84.2 to 93.4)90.5 (86.5 to 94.6)91.0 (86.9 to 95.1)
Week 9690.1 (85.7 to 94.6)87.2 (82.6 to 91.7)90.3 (86.1 to 94.6)
Week 10087.8 (83.1 to 92.6)86.1 (81.4 to 90.8)92.0 (88.1 to 95.9)
SecondaryPercentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, average of Weeks 48, 52, and 56
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Avoiding a Loss of ≥15 Letters98.1 (96.5 to 99.7)98.6 (97.2 to 100.0)98.9 (97.6 to 100.0)
Avoiding a Loss of ≥10 Letters96.3 (94.1 to 98.5)98.2 (96.6 to 99.8)98.1 (96.5 to 99.7)
Avoiding a Loss of ≥5 Letters95.2 (92.7 to 97.7)96.7 (94.7 to 98.8)96.3 (94.1 to 98.5)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -0.8 · 95% CI -2.8 to 1.3
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -0.3 · 95% CI -2.2 to 1.5
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -1.8 · 95% CI -4.6 to 0.9
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.0 · 95% CI -2.2 to 2.2
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -1.1 · 95% CI -4.5 to 2.2
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.4 · 95% CI -2.6 to 3.4
SecondaryPercentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 4100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)
Week 899.7 (99.0 to 100.0)100.0 (100.0 to 100.0)99.3 (98.4 to 100.0)
Week 1299.3 (98.5 to 100.0)100.0 (100.0 to 100.0)99.7 (99.0 to 100.0)
Week 1699.7 (99.0 to 100.0)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)
Week 2099.3 (98.4 to 100.0)99.3 (98.4 to 100.0)99.6 (99.0 to 100.0)
Week 2499.6 (98.9 to 100.0)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)
Week 2899.3 (98.2 to 100.0)99.7 (99.0 to 100.0)99.6 (99.0 to 100.0)
Week 3299.6 (98.8 to 100.0)100.0 (100.0 to 100.0)99.3 (98.3 to 100.0)
Week 3699.2 (98.0 to 100.0)99.2 (98.2 to 100.0)99.6 (98.8 to 100.0)
Week 4098.8 (97.5 to 100.0)99.3 (98.2 to 100.0)99.6 (98.8 to 100.0)
Week 4498.8 (97.5 to 100.0)98.9 (97.7 to 100.0)100.0 (100.0 to 100.0)
Week 4898.4 (96.9 to 100.0)98.1 (96.5 to 99.7)99.3 (98.3 to 100.0)
Week 5297.2 (95.2 to 99.2)98.1 (96.5 to 99.7)98.4 (96.8 to 99.9)
Week 5698.4 (96.9 to 99.9)98.5 (97.0 to 100.0)98.4 (96.9 to 99.9)
Week 6098.1 (96.4 to 99.7)98.5 (97.0 to 99.9)99.2 (98.1 to 100.0)
Week 6498.8 (97.4 to 100.0)97.7 (95.8 to 99.5)98.8 (97.5 to 100.0)
Week 6899.1 (98.0 to 100.0)98.0 (96.3 to 99.7)98.8 (97.5 to 100.0)
Week 7297.2 (95.1 to 99.2)98.8 (97.5 to 100.0)98.8 (97.5 to 100.0)
Week 7696.6 (94.4 to 98.9)98.0 (96.3 to 99.7)98.0 (96.3 to 99.7)
Week 8097.6 (95.7 to 99.5)96.9 (94.8 to 99.0)99.1 (98.0 to 100.0)
Week 8497.1 (95.0 to 99.2)98.1 (96.5 to 99.7)99.1 (98.0 to 100.0)
Week 8897.1 (95.0 to 99.2)97.2 (95.2 to 99.2)97.9 (96.1 to 99.7)
Week 9297.1 (95.0 to 99.2)97.4 (95.5 to 99.3)98.3 (96.6 to 99.9)
Week 9697.4 (95.3 to 99.4)96.6 (94.4 to 98.8)97.8 (95.9 to 99.7)
Week 10096.3 (93.9 to 98.7)97.0 (94.9 to 99.0)98.4 (96.8 to 99.9)
SecondaryPercentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 498.7 (97.5 to 99.9)100.0 (100.0 to 100.0)99.4 (98.5 to 100.0)
Week 898.4 (97.0 to 99.8)100.0 (100.0 to 100.0)99.0 (97.9 to 100.0)
Week 1298.7 (97.4 to 100.0)100.0 (100.0 to 100.0)99.3 (98.4 to 100.0)
Week 1699.3 (98.4 to 100.0)99.3 (98.4 to 100.0)99.7 (99.0 to 100.0)
Week 2099.0 (97.8 to 100.0)98.6 (97.3 to 100.0)99.3 (98.4 to 100.0)
Week 2498.6 (97.2 to 100.0)99.7 (99.0 to 100.0)99.3 (98.4 to 100.0)
Week 2897.4 (95.6 to 99.3)99.0 (97.8 to 100.0)98.6 (97.2 to 100.0)
Week 3299.2 (98.1 to 100.0)98.5 (97.0 to 99.9)98.5 (97.1 to 99.9)
Week 3698.4 (96.9 to 99.9)98.9 (97.6 to 100.0)99.2 (98.2 to 100.0)
Week 4097.7 (95.9 to 99.5)99.3 (98.2 to 100.0)98.5 (97.0 to 99.9)
Week 4497.3 (95.4 to 99.3)98.2 (96.6 to 99.8)99.2 (98.2 to 100.0)
Week 4898.1 (96.4 to 99.7)97.8 (96.0 to 99.5)98.5 (97.1 to 99.9)
Week 5295.3 (92.8 to 97.9)97.0 (95.0 to 99.0)96.8 (94.6 to 99.0)
Week 5697.2 (95.2 to 99.2)98.1 (96.5 to 99.7)96.5 (94.3 to 98.7)
Week 6096.9 (94.8 to 99.0)97.3 (95.4 to 99.3)98.1 (96.4 to 99.7)
Week 6498.0 (96.3 to 99.7)96.5 (94.2 to 98.7)98.1 (96.4 to 99.7)
Week 6896.9 (94.7 to 99.0)97.6 (95.8 to 99.5)98.4 (96.9 to 100.0)
Week 7296.0 (93.6 to 98.4)98.0 (96.4 to 99.7)97.6 (95.7 to 99.5)
Week 7695.9 (93.4 to 98.4)95.6 (93.1 to 98.1)97.6 (95.7 to 99.5)
Week 8096.3 (94.0 to 98.7)96.2 (93.8 to 98.5)97.6 (95.9 to 99.5)
Week 8495.5 (93.0 to 98.1)97.0 (95.0 to 99.0)99.1 (98.0 to 100.0)
Week 8895.0 (92.3 to 97.7)95.6 (93.1 to 98.1)96.7 (94.5 to 98.9)
Week 9295.9 (93.3 to 98.4)96.5 (94.3 to 98.7)97.5 (95.5 to 99.5)
Week 9696.9 (94.7 to 99.2)94.3 (91.5 to 97.1)96.6 (94.3 to 98.9)
Week 10094.3 (91.5 to 97.2)94.6 (91.8 to 97.3)97.1 (95.1 to 99.2)
SecondaryPercentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 497.7 (96.1 to 99.4)97.4 (95.6 to 99.1)96.4 (94.4 to 98.4)
Week 896.4 (94.4 to 98.5)98.7 (97.5 to 100.0)97.3 (95.5 to 99.1)
Week 1298.0 (96.5 to 99.6)98.0 (96.4 to 99.6)98.4 (97.0 to 99.8)
Week 1697.3 (95.5 to 99.1)98.6 (97.3 to 100.0)98.7 (97.4 to 100.0)
Week 2096.9 (95.0 to 98.9)97.2 (95.4 to 99.1)97.3 (95.4 to 99.1)
Week 2496.9 (94.9 to 98.9)96.9 (94.9 to 98.9)96.6 (94.6 to 98.7)
Week 2896.4 (94.2 to 98.6)97.6 (95.8 to 99.3)96.1 (93.9 to 98.4)
Week 3296.6 (94.4 to 98.8)97.4 (95.5 to 99.3)97.5 (95.6 to 99.3)
Week 3696.2 (93.9 to 98.5)97.3 (95.4 to 99.3)97.7 (96.0 to 99.5)
Week 4095.2 (92.6 to 97.7)95.8 (93.4 to 98.2)97.7 (95.9 to 99.5)
Week 4495.2 (92.6 to 97.7)96.7 (94.6 to 98.8)95.8 (93.4 to 98.2)
Week 4896.6 (94.4 to 98.8)96.7 (94.5 to 98.8)96.9 (94.9 to 99.0)
Week 5294.2 (91.4 to 97.0)95.9 (93.5 to 98.3)94.9 (92.2 to 97.6)
Week 5696.0 (93.7 to 98.4)96.2 (93.8 to 98.5)95.0 (92.4 to 97.6)
Week 6094.0 (91.2 to 96.8)96.2 (93.8 to 98.5)97.0 (94.9 to 99.0)
Week 6495.7 (93.2 to 98.2)96.1 (93.8 to 98.5)96.1 (93.8 to 98.4)
Week 6894.8 (92.1 to 97.6)96.4 (94.1 to 98.7)96.1 (93.8 to 98.5)
Week 7293.3 (90.3 to 96.4)95.3 (92.7 to 97.9)94.4 (91.5 to 97.2)
Week 7692.6 (89.4 to 95.9)94.8 (92.0 to 97.5)95.2 (92.6 to 97.8)
Week 8094.0 (91.0 to 96.9)93.4 (90.4 to 96.4)94.0 (91.1 to 96.9)
Week 8492.8 (89.6 to 96.0)95.8 (93.4 to 98.2)97.2 (95.1 to 99.2)
Week 8889.8 (86.0 to 93.5)92.6 (89.4 to 95.8)94.7 (91.9 to 97.5)
Week 9293.8 (90.8 to 96.8)92.7 (89.5 to 95.8)96.7 (94.4 to 98.9)
Week 9694.9 (92.0 to 97.7)92.3 (89.1 to 95.5)95.0 (92.3 to 97.8)
Week 10091.1 (87.6 to 94.6)88.9 (85.1 to 92.6)96.4 (94.1 to 98.6)
SecondaryPercentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, average of Weeks 48, 52, and 56
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Avoiding a Loss of ≥15 Letters97.9 (96.0 to 99.9)98.1 (96.3 to 99.9)99.0 (97.7 to 100.0)
Avoiding a Loss of ≥10 Letters96.5 (93.9 to 99.0)97.7 (95.7 to 99.7)98.6 (97.0 to 100.0)
Avoiding a Loss of ≥5 Letters95.0 (91.9 to 98.0)95.8 (93.1 to 98.5)96.2 (93.6 to 98.8)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -1.1 · 95% CI -3.5 to 1.3
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -0.9 · 95% CI -3.1 to 1.3
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -2.1 · 95% CI -5.1 to 0.9
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -0.9 · 95% CI -3.5 to 1.6
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -1.2 · 95% CI -5.2 to 2.8
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -0.4 · 95% CI -4.1 to 3.3
SecondaryPercentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 4100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)
Week 899.6 (98.7 to 100.0)100.0 (100.0 to 100.0)99.6 (98.8 to 100.0)
Week 1299.6 (98.7 to 100.0)100.0 (100.0 to 100.0)99.6 (98.7 to 100.0)
Week 1699.6 (98.7 to 100.0)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)
Week 2099.1 (97.9 to 100.0)99.1 (97.9 to 100.0)100.0 (100.0 to 100.0)
Week 2499.5 (98.6 to 100.0)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)
Week 2899.0 (97.6 to 100.0)99.6 (98.7 to 100.0)99.5 (98.6 to 100.0)
Week 3299.5 (98.4 to 100.0)100.0 (100.0 to 100.0)99.0 (97.7 to 100.0)
Week 3698.9 (97.3 to 100.0)99.0 (97.6 to 100.0)99.5 (98.4 to 100.0)
Week 4098.4 (96.6 to 100.0)99.0 (97.7 to 100.0)99.5 (98.4 to 100.0)
Week 4498.9 (97.5 to 100.0)98.6 (97.0 to 100.0)100.0 (100.0 to 100.0)
Week 4898.4 (96.6 to 100.0)97.6 (95.5 to 99.7)99.0 (97.7 to 100.0)
Week 5296.8 (94.3 to 99.3)97.6 (95.5 to 99.7)98.4 (96.6 to 100.0)
Week 5698.4 (96.7 to 100.0)98.1 (96.2 to 99.9)98.5 (96.7 to 100.0)
Week 6097.4 (95.2 to 99.6)98.0 (96.1 to 99.9)99.0 (97.5 to 100.0)
Week 6498.4 (96.5 to 100.0)97.0 (94.6 to 99.4)98.4 (96.7 to 100.0)
Week 6898.9 (97.3 to 100.0)97.4 (95.2 to 99.6)98.4 (96.7 to 100.0)
Week 7296.2 (93.4 to 98.9)98.5 (96.8 to 100.0)98.4 (96.6 to 100.0)
Week 7695.5 (92.4 to 98.5)97.4 (95.2 to 99.6)97.9 (95.9 to 99.9)
Week 8096.7 (94.1 to 99.3)96.6 (94.1 to 99.1)98.8 (97.3 to 100.0)
Week 8496.1 (93.3 to 98.9)98.0 (96.1 to 99.9)99.5 (98.4 to 100.0)
Week 8896.1 (93.2 to 98.9)97.5 (95.3 to 99.6)97.7 (95.5 to 99.9)
Week 9296.1 (93.2 to 98.9)97.0 (94.7 to 99.3)98.3 (96.4 to 100.0)
Week 9697.1 (94.6 to 99.6)96.1 (93.4 to 98.7)98.9 (97.3 to 100.0)
Week 10096.1 (93.3 to 98.9)97.1 (94.8 to 99.4)98.4 (96.6 to 100.0)
SecondaryPercentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 499.6 (98.7 to 100.0)100.0 (100.0 to 100.0)99.2 (98.0 to 100.0)
Week 898.3 (96.6 to 100.0)100.0 (100.0 to 100.0)99.6 (98.8 to 100.0)
Week 1299.1 (97.9 to 100.0)100.0 (100.0 to 100.0)99.6 (98.7 to 100.0)
Week 1699.1 (97.9 to 100.0)99.1 (97.9 to 100.0)100.0 (100.0 to 100.0)
Week 2099.1 (97.9 to 100.0)98.3 (96.6 to 99.9)100.0 (100.0 to 100.0)
Week 2499.1 (97.8 to 100.0)99.6 (98.7 to 100.0)99.1 (97.9 to 100.0)
Week 2898.0 (96.1 to 99.9)98.7 (97.2 to 100.0)98.6 (97.1 to 100.0)
Week 3299.5 (98.4 to 100.0)98.0 (96.1 to 99.9)98.1 (96.2 to 99.9)
Week 3697.9 (95.8 to 99.9)98.5 (96.8 to 100.0)99.0 (97.6 to 100.0)
Week 4096.9 (94.5 to 99.3)99.0 (97.7 to 100.0)97.9 (95.9 to 99.9)
Week 4497.4 (95.2 to 99.6)97.6 (95.6 to 99.7)99.0 (97.6 to 100.0)
Week 4897.9 (95.9 to 99.9)97.1 (94.9 to 99.4)98.5 (96.9 to 100.0)
Week 5295.3 (92.3 to 98.3)96.2 (93.6 to 98.8)96.8 (94.4 to 99.3)
Week 5697.4 (95.2 to 99.6)97.6 (95.5 to 99.7)96.4 (93.9 to 99.0)
Week 6096.4 (93.8 to 99.0)96.5 (93.9 to 99.0)97.9 (95.9 to 99.9)
Week 6497.3 (95.0 to 99.6)96.5 (94.0 to 99.1)97.4 (95.2 to 99.6)
Week 6896.8 (94.3 to 99.3)96.9 (94.6 to 99.3)97.9 (95.9 to 99.9)
Week 7295.1 (92.0 to 98.2)98.0 (96.1 to 99.9)97.3 (95.0 to 99.6)
Week 7694.9 (91.7 to 98.2)94.3 (91.1 to 97.6)97.4 (95.1 to 99.6)
Week 8095.0 (91.8 to 98.2)95.6 (92.8 to 98.4)97.3 (94.9 to 99.6)
Week 8494.0 (90.5 to 97.4)97.1 (94.7 to 99.4)99.5 (98.4 to 100.0)
Week 8893.9 (90.4 to 97.4)95.4 (92.5 to 98.3)96.1 (93.3 to 98.9)
Week 9295.0 (91.8 to 98.2)96.5 (94.0 to 99.0)97.2 (94.9 to 99.6)
Week 9696.5 (93.7 to 99.3)93.6 (90.2 to 97.0)97.2 (94.8 to 99.6)
Week 10093.9 (90.4 to 97.4)94.6 (91.5 to 97.7)97.3 (94.9 to 99.6)
SecondaryPercentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 498.7 (97.3 to 100.0)97.5 (95.5 to 99.5)97.0 (94.9 to 99.2)
Week 896.5 (94.2 to 98.8)99.2 (98.1 to 100.0)98.3 (96.6 to 99.9)
Week 1298.3 (96.6 to 99.9)98.7 (97.3 to 100.0)98.7 (97.3 to 100.0)
Week 1697.8 (95.8 to 99.7)98.3 (96.6 to 99.9)98.7 (97.3 to 100.0)
Week 2097.3 (95.2 to 99.4)96.5 (94.2 to 98.9)97.8 (95.9 to 99.7)
Week 2497.7 (95.7 to 99.7)96.1 (93.5 to 98.6)96.5 (94.1 to 98.9)
Week 2896.6 (94.1 to 99.0)97.3 (95.2 to 99.4)96.8 (94.5 to 99.1)
Week 3297.4 (95.1 to 99.6)96.6 (94.1 to 99.1)97.6 (95.5 to 99.7)
Week 3696.3 (93.6 to 99.0)97.6 (95.4 to 99.7)98.1 (96.2 to 99.9)
Week 4094.5 (91.3 to 97.6)95.6 (92.7 to 98.4)96.9 (94.5 to 99.3)
Week 4495.9 (93.2 to 98.7)95.8 (93.1 to 98.5)96.5 (93.9 to 99.0)
Week 4896.4 (93.8 to 99.0)95.7 (93.0 to 98.5)97.5 (95.4 to 99.7)
Week 5294.3 (91.1 to 97.6)94.8 (91.7 to 97.8)94.4 (91.2 to 97.6)
Week 5695.8 (93.0 to 98.6)95.6 (92.9 to 98.4)94.4 (91.3 to 97.6)
Week 6094.4 (91.2 to 97.6)96.0 (93.3 to 98.7)96.9 (94.6 to 99.3)
Week 6495.2 (92.2 to 98.3)96.0 (93.3 to 98.7)95.8 (93.0 to 98.6)
Week 6894.6 (91.4 to 97.9)95.9 (93.2 to 98.7)96.4 (93.8 to 99.0)
Week 7292.6 (88.8 to 96.3)95.9 (93.2 to 98.7)94.7 (91.4 to 97.9)
Week 7691.1 (86.9 to 95.3)93.8 (90.5 to 97.2)94.7 (91.5 to 97.9)
Week 8092.8 (89.0 to 96.6)92.6 (89.1 to 96.2)94.2 (90.9 to 97.5)
Week 8491.9 (87.9 to 95.8)96.1 (93.4 to 98.7)96.9 (94.4 to 99.3)
Week 8888.3 (83.6 to 93.0)91.9 (88.1 to 95.7)93.5 (89.9 to 97.0)
Week 9292.7 (88.9 to 96.5)92.5 (88.9 to 96.2)96.7 (94.1 to 99.3)
Week 9694.8 (91.4 to 98.1)91.5 (87.7 to 95.4)95.2 (92.1 to 98.3)
Week 10090.6 (86.4 to 94.9)88.1 (83.7 to 92.5)96.8 (94.2 to 99.3)
SecondaryPercentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, average of Weeks 48, 52, and 56
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
ITT Population32.1 (26.6 to 37.6)39.1 (33.5 to 44.7)37.0 (31.5 to 42.5)
Treatment-Naive Population31.5 (25.1 to 38.0)39.2 (32.8 to 45.5)40.2 (33.7 to 46.6)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -4.9 · 95% CI -12.6 to 2.9
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 2.0 · 95% CI -5.9 to 9.8
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -8.6 · 95% CI -17.8 to 0.5
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -0.9 · 95% CI -9.9 to 8.2
SecondaryPercentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 48.7 (5.6 to 11.8)14.6 (10.8 to 18.4)13.3 (9.6 to 17.0)
Week 815.3 (11.3 to 19.3)20.1 (15.9 to 24.4)19.9 (15.6 to 24.3)
Week 1217.9 (13.6 to 22.1)25.7 (21.1 to 30.4)25.3 (20.6 to 30.0)
Week 1624.1 (19.2 to 28.9)29.1 (24.2 to 34.0)25.2 (20.5 to 30.0)
Week 2030.1 (24.9 to 35.2)30.8 (25.6 to 35.9)27.7 (22.8 to 32.6)
Week 2431.3 (26.0 to 36.5)37.8 (32.5 to 43.2)30.9 (25.7 to 36.0)
Week 2828.3 (23.1 to 33.5)32.6 (27.4 to 37.8)35.0 (29.7 to 40.4)
Week 3233.7 (28.0 to 39.3)38.8 (33.2 to 44.4)31.0 (25.8 to 36.2)
Week 3629.6 (24.1 to 35.0)42.4 (36.8 to 48.1)35.6 (30.0 to 41.1)
Week 4032.9 (27.4 to 38.5)40.4 (34.7 to 46.2)33.8 (28.2 to 39.4)
Week 4432.1 (26.5 to 37.7)39.7 (34.1 to 45.3)39.9 (34.2 to 45.7)
Week 4835.7 (30.0 to 41.5)41.8 (36.1 to 47.6)41.7 (36.0 to 47.4)
Week 5235.7 (29.9 to 41.4)40.2 (34.5 to 45.8)41.7 (35.8 to 47.6)
Week 5643.1 (37.1 to 49.1)42.6 (36.7 to 48.4)35.7 (30.1 to 41.4)
Week 6039.5 (33.7 to 45.3)45.0 (39.1 to 51.0)40.6 (34.8 to 46.3)
Week 6442.1 (36.1 to 48.1)44.0 (38.2 to 49.8)37.9 (32.1 to 43.7)
Week 6842.2 (36.2 to 48.2)45.6 (39.7 to 51.6)40.3 (34.5 to 46.2)
Week 7239.8 (33.9 to 45.8)40.5 (34.8 to 46.2)37.7 (31.8 to 43.6)
Week 7642.2 (36.1 to 48.4)47.7 (41.8 to 53.5)42.9 (36.8 to 49.0)
Week 8042.9 (36.8 to 49.0)44.8 (39.0 to 50.5)41.9 (35.9 to 47.8)
Week 8442.4 (36.3 to 48.5)43.0 (37.2 to 48.7)42.9 (36.9 to 48.9)
Week 8841.2 (35.1 to 47.3)41.7 (36.1 to 47.4)40.0 (34.1 to 46.0)
Week 9242.5 (36.4 to 48.5)43.6 (37.8 to 49.4)42.7 (36.7 to 48.7)
Week 9644.9 (38.7 to 51.1)42.4 (36.6 to 48.1)42.7 (36.6 to 48.7)
Week 10043.5 (37.5 to 49.6)41.8 (36.1 to 47.5)44.7 (38.6 to 50.8)
SecondaryPercentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 49.8 (6.0 to 13.5)17.0 (12.4 to 21.6)15.2 (10.7 to 19.8)
Week 816.0 (11.3 to 20.7)20.9 (16.1 to 25.7)22.2 (16.9 to 27.4)
Week 1219.2 (14.1 to 24.2)25.6 (20.3 to 30.9)28.5 (22.9 to 34.1)
Week 1624.9 (19.2 to 30.5)29.5 (23.8 to 35.2)27.9 (22.2 to 33.6)
Week 2031.0 (25.0 to 37.0)30.4 (24.6 to 36.1)30.6 (24.8 to 36.4)
Week 2432.5 (26.3 to 38.7)38.2 (32.1 to 44.3)33.3 (27.3 to 39.4)
Week 2826.9 (20.9 to 32.9)32.0 (26.2 to 37.8)38.5 (32.2 to 44.8)
Week 3233.3 (26.7 to 39.9)40.5 (34.0 to 46.9)35.4 (29.0 to 41.7)
Week 3629.5 (23.1 to 36.0)44.8 (38.3 to 51.3)38.4 (31.9 to 44.8)
Week 4031.5 (25.1 to 37.9)41.1 (34.5 to 47.7)37.1 (30.4 to 43.7)
Week 4431.1 (24.7 to 37.6)42.9 (36.4 to 49.5)42.7 (36.0 to 49.4)
Week 4837.5 (30.7 to 44.3)41.9 (35.3 to 48.5)44.9 (38.2 to 51.6)
Week 5235.5 (28.9 to 42.2)39.2 (32.8 to 45.6)43.8 (36.9 to 50.6)
Week 5643.3 (36.3 to 50.3)43.1 (36.5 to 49.7)38.9 (32.2 to 45.5)
Week 6039.4 (32.6 to 46.2)46.7 (39.9 to 53.5)43.6 (36.8 to 50.4)
Week 6443.0 (36.0 to 50.0)46.4 (39.8 to 53.1)38.7 (32.0 to 45.3)
Week 6843.7 (36.6 to 50.7)47.9 (41.1 to 54.7)42.2 (35.4 to 49.0)
Week 7240.7 (33.7 to 47.8)42.1 (35.5 to 48.7)39.3 (32.5 to 46.2)
Week 7644.6 (37.3 to 51.8)49.9 (43.3 to 56.6)43.8 (36.8 to 50.8)
Week 8044.6 (37.3 to 51.8)46.6 (40.1 to 53.2)46.1 (39.1 to 53.1)
Week 8442.7 (35.6 to 49.9)45.2 (38.6 to 51.7)45.7 (38.7 to 52.7)
Week 8841.3 (34.2 to 48.5)42.7 (36.3 to 49.2)42.5 (35.5 to 49.6)
Week 9243.4 (36.3 to 50.6)45.5 (38.9 to 52.1)43.9 (36.9 to 50.8)
Week 9646.7 (39.3 to 54.1)43.6 (37.2 to 50.1)44.7 (37.7 to 51.8)
Week 10044.1 (37.0 to 51.3)44.4 (37.9 to 50.9)45.8 (38.8 to 52.9)
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥69 vs. \<69 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, average of Weeks 48, 52, and 56
Reported as:
Number · Percentage of participants
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
ITT Population71.6 (66.5 to 76.6)77.1 (72.4 to 81.8)74.8 (69.9 to 79.6)
Treatment-Naive Population72.7 (66.9 to 78.5)75.7 (70.3 to 81.1)77.4 (72.2 to 82.7)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -3.2 · 95% CI -10.2 to 3.8
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 2.4 · 95% CI -4.3 to 9.2
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -4.7 · 95% CI -12.6 to 3.1
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -1.3 · 95% CI -8.9 to 6.4
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥69 vs. \<69 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 453.3 (48.4 to 58.1)60.0 (55.1 to 64.8)57.5 (52.6 to 62.4)
Week 860.0 (55.1 to 64.9)65.5 (60.8 to 70.1)66.1 (61.4 to 70.8)
Week 1264.4 (59.4 to 69.3)69.3 (64.6 to 74.0)68.8 (64.1 to 73.6)
Week 1666.1 (61.1 to 71.2)70.6 (65.8 to 75.3)74.7 (70.1 to 79.2)
Week 2070.3 (65.4 to 75.3)69.7 (64.9 to 74.6)70.3 (65.5 to 75.1)
Week 2471.0 (66.1 to 76.0)76.0 (71.4 to 80.6)71.0 (66.3 to 75.8)
Week 2871.5 (66.5 to 76.4)74.5 (69.9 to 79.1)75.1 (70.4 to 79.8)
Week 3271.4 (66.3 to 76.5)74.1 (69.2 to 79.0)74.9 (70.1 to 79.7)
Week 3671.8 (66.8 to 76.9)79.4 (74.7 to 84.1)73.2 (68.1 to 78.2)
Week 4069.3 (64.2 to 74.4)75.1 (70.2 to 80.1)73.6 (68.5 to 78.7)
Week 4470.6 (65.4 to 75.7)77.7 (72.9 to 82.5)73.4 (68.3 to 78.4)
Week 4873.4 (68.4 to 78.4)78.3 (73.6 to 83.0)72.7 (67.6 to 77.8)
Week 5269.3 (63.9 to 74.6)76.6 (71.7 to 81.4)75.2 (70.2 to 80.2)
Week 5674.9 (69.9 to 79.9)79.5 (74.8 to 84.2)72.2 (67.0 to 77.4)
Week 6071.8 (66.6 to 76.9)76.6 (71.6 to 81.5)75.9 (70.9 to 80.9)
Week 6474.9 (69.8 to 79.9)76.2 (71.4 to 81.0)71.4 (66.3 to 76.5)
Week 6874.4 (69.2 to 79.7)78.0 (73.2 to 82.8)73.9 (68.9 to 78.9)
Week 7273.9 (68.6 to 79.1)76.8 (72.0 to 81.7)71.0 (65.8 to 76.1)
Week 7672.6 (67.2 to 78.0)77.0 (72.0 to 82.0)76.0 (71.1 to 81.0)
Week 8074.6 (69.3 to 79.9)77.5 (72.5 to 82.4)73.8 (68.7 to 78.9)
Week 8473.7 (68.4 to 79.1)77.2 (72.3 to 82.1)77.3 (72.5 to 82.2)
Week 8872.2 (66.7 to 77.7)76.2 (71.2 to 81.3)73.3 (68.0 to 78.5)
Week 9275.3 (70.0 to 80.6)78.4 (73.4 to 83.3)77.4 (72.6 to 82.2)
Week 9675.9 (70.6 to 81.2)74.3 (69.0 to 79.5)73.4 (68.3 to 78.5)
Week 10075.9 (70.7 to 81.1)70.3 (64.9 to 75.7)75.7 (70.8 to 80.7)
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥69 vs. \<69 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 455.7 (50.1 to 61.2)60.4 (55.0 to 65.8)60.4 (54.9 to 65.9)
Week 862.0 (56.5 to 67.6)66.5 (61.3 to 71.6)69.6 (64.3 to 74.8)
Week 1266.2 (60.5 to 71.8)69.3 (64.1 to 74.5)70.6 (65.3 to 75.9)
Week 1668.5 (62.8 to 74.2)68.5 (63.1 to 74.0)75.8 (70.8 to 80.9)
Week 2072.7 (67.1 to 78.2)67.8 (62.2 to 73.4)72.0 (66.7 to 77.3)
Week 2473.7 (68.2 to 79.3)74.5 (69.2 to 79.8)72.6 (67.3 to 77.9)
Week 2873.7 (68.2 to 79.3)73.1 (67.8 to 78.4)77.0 (71.8 to 82.2)
Week 3271.8 (65.8 to 77.7)72.4 (66.7 to 78.1)75.8 (70.4 to 81.2)
Week 3674.7 (68.9 to 80.5)79.4 (74.0 to 84.7)73.4 (67.6 to 79.1)
Week 4070.6 (64.7 to 76.6)74.6 (68.9 to 80.3)75.8 (70.2 to 81.4)
Week 4471.1 (65.2 to 77.1)76.9 (71.3 to 82.4)76.4 (70.8 to 82.0)
Week 4874.3 (68.6 to 80.0)75.7 (70.2 to 81.2)75.3 (69.8 to 80.9)
Week 5271.7 (65.6 to 77.7)74.4 (68.7 to 80.1)77.5 (71.9 to 83.0)
Week 5676.9 (71.3 to 82.5)77.9 (72.4 to 83.4)74.0 (68.2 to 79.7)
Week 6073.4 (67.5 to 79.3)75.2 (69.4 to 81.0)78.3 (72.8 to 83.8)
Week 6477.0 (71.2 to 82.7)75.5 (69.9 to 81.0)74.4 (68.9 to 80.0)
Week 6877.6 (71.7 to 83.5)77.9 (72.4 to 83.3)75.5 (69.9 to 81.0)
Week 7276.7 (70.7 to 82.6)75.9 (70.3 to 81.4)74.5 (68.9 to 80.1)
Week 7672.7 (66.3 to 79.1)75.8 (70.1 to 81.5)78.0 (72.6 to 83.3)
Week 8076.4 (70.2 to 82.6)76.8 (71.2 to 82.5)76.5 (70.9 to 82.1)
Week 8475.7 (69.5 to 81.9)77.8 (72.3 to 83.3)77.8 (72.4 to 83.2)
Week 8871.8 (65.2 to 78.3)75.7 (69.9 to 81.5)76.0 (70.1 to 81.9)
Week 9275.9 (69.7 to 82.1)77.7 (71.9 to 83.4)79.9 (74.7 to 85.2)
Week 9677.3 (71.1 to 83.4)73.5 (67.4 to 79.5)75.5 (69.9 to 81.2)
Week 10077.6 (71.6 to 83.6)70.8 (64.6 to 76.9)77.0 (71.4 to 82.5)
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, average of Weeks 48, 52, and 56
Reported as:
Number · Percentage of participants
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
ITT Population2.3 (0.5 to 4.1)1.9 (0.3 to 3.5)1.7 (0.3 to 3.2)
Treatment-Naive Population2.6 (0.4 to 4.8)1.9 (0.1 to 3.7)1.8 (0.1 to 3.5)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.6 · 95% CI -1.8 to 2.9
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.0 · 95% CI -2.2 to 2.3
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.8 · 95% CI -2.0 to 3.6
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.0 · 95% CI -2.6 to 2.5
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement invisual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 41.9 (0.4 to 3.4)2.6 (0.9 to 4.3)1.6 (0.2 to 3.0)
Week 82.0 (0.4 to 3.5)3.0 (1.1 to 4.8)2.0 (0.4 to 3.5)
Week 121.6 (0.2 to 3.0)2.0 (0.5 to 3.5)1.6 (0.2 to 3.0)
Week 160.7 (0.0 to 1.6)2.1 (0.5 to 3.7)1.6 (0.2 to 3.0)
Week 201.3 (0.0 to 2.7)1.7 (0.3 to 3.2)1.7 (0.2 to 3.1)
Week 240.7 (0.0 to 1.6)1.7 (0.3 to 3.2)1.7 (0.3 to 3.1)
Week 281.4 (0.1 to 2.8)1.4 (0.1 to 2.8)1.4 (0.1 to 2.7)
Week 321.1 (0.0 to 2.4)1.2 (0.0 to 2.4)1.8 (0.2 to 3.3)
Week 361.6 (0.1 to 3.1)1.6 (0.1 to 3.1)1.5 (0.1 to 3.0)
Week 401.5 (0.1 to 3.0)2.3 (0.5 to 4.1)1.5 (0.1 to 2.9)
Week 443.1 (1.0 to 5.2)1.9 (0.3 to 3.6)1.4 (0.1 to 2.8)
Week 481.6 (0.1 to 3.1)2.3 (0.5 to 4.1)1.8 (0.3 to 3.3)
Week 522.0 (0.3 to 3.8)1.5 (0.1 to 3.0)1.5 (0.1 to 2.9)
Week 561.5 (0.0 to 3.0)1.6 (0.1 to 3.1)1.9 (0.3 to 3.5)
Week 601.9 (0.3 to 3.5)1.2 (0.0 to 2.5)1.4 (0.1 to 2.8)
Week 641.2 (0.0 to 2.6)2.5 (0.6 to 4.3)1.8 (0.2 to 3.3)
Week 681.3 (0.0 to 2.7)2.4 (0.6 to 4.3)1.8 (0.3 to 3.4)
Week 721.3 (0.0 to 2.7)1.6 (0.1 to 3.1)1.5 (0.1 to 2.9)
Week 760.9 (0.0 to 2.1)1.6 (0.1 to 3.2)3.4 (1.3 to 5.6)
Week 800.9 (0.0 to 2.1)2.0 (0.3 to 3.8)3.0 (1.0 to 5.0)
Week 840.9 (0.0 to 2.1)1.6 (0.1 to 3.2)1.0 (0.0 to 2.2)
Week 881.3 (0.0 to 2.7)1.7 (0.1 to 3.2)2.0 (0.3 to 3.8)
Week 922.2 (0.3 to 4.0)2.1 (0.4 to 3.9)2.8 (0.8 to 4.8)
Week 961.7 (0.1 to 3.4)2.1 (0.3 to 3.8)0.9 (0.0 to 2.1)
Week 1002.5 (0.5 to 4.5)2.1 (0.3 to 3.8)1.2 (0.0 to 2.6)
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 41.7 (0.1 to 3.3)2.9 (0.8 to 4.9)1.3 (0.0 to 2.7)
Week 82.2 (0.3 to 4.0)3.3 (1.1 to 5.5)2.1 (0.3 to 3.9)
Week 121.3 (0.0 to 2.7)2.1 (0.3 to 3.9)1.7 (0.1 to 3.3)
Week 160.5 (0.0 to 1.3)2.2 (0.3 to 4.0)1.7 (0.1 to 3.3)
Week 201.3 (0.0 to 2.8)1.7 (0.1 to 3.4)1.7 (0.1 to 3.4)
Week 240.5 (0.0 to 1.4)1.7 (0.1 to 3.4)1.3 (0.0 to 2.7)
Week 281.0 (0.0 to 2.4)1.3 (0.0 to 2.9)1.3 (0.0 to 2.8)
Week 321.1 (0.0 to 2.5)1.0 (0.0 to 2.3)1.9 (0.1 to 3.7)
Week 361.7 (0.0 to 3.5)1.0 (0.0 to 2.4)1.5 (0.0 to 3.1)
Week 401.6 (0.0 to 3.3)2.0 (0.1 to 3.9)1.4 (0.0 to 3.0)
Week 442.7 (0.4 to 4.9)2.0 (0.1 to 3.8)1.4 (0.0 to 2.9)
Week 481.6 (0.0 to 3.4)2.4 (0.3 to 4.5)1.9 (0.1 to 3.7)
Week 522.7 (0.4 to 5.0)1.9 (0.1 to 3.8)1.4 (0.0 to 3.0)
Week 561.0 (0.0 to 2.5)1.5 (0.0 to 3.1)2.0 (0.1 to 3.9)
Week 602.1 (0.1 to 4.1)1.0 (0.0 to 2.4)1.9 (0.1 to 3.8)
Week 641.6 (0.0 to 3.5)2.0 (0.1 to 4.0)1.9 (0.1 to 3.7)
Week 681.1 (0.0 to 2.7)1.6 (0.0 to 3.3)1.9 (0.1 to 3.7)
Week 721.7 (0.0 to 3.6)1.0 (0.0 to 2.4)1.4 (0.0 to 3.0)
Week 761.2 (0.0 to 2.8)1.5 (0.0 to 3.2)3.5 (1.0 to 6.0)
Week 801.2 (0.0 to 2.8)2.0 (0.1 to 4.0)3.5 (1.0 to 6.0)
Week 841.2 (0.0 to 2.8)1.0 (0.0 to 2.4)1.4 (0.0 to 2.9)
Week 881.7 (0.0 to 3.7)1.0 (0.0 to 2.4)2.1 (0.1 to 4.2)
Week 922.4 (0.1 to 4.6)1.5 (0.0 to 3.3)2.6 (0.3 to 4.9)
Week 961.3 (0.0 to 3.0)2.1 (0.1 to 4.0)0.6 (0.0 to 1.7)
Week 1002.3 (0.1 to 4.5)2.1 (0.1 to 4.1)1.1 (0.0 to 2.6)
SecondaryPercentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 16, 52, and 96
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 1636.7 (31.2 to 42.3)35.0 (29.6 to 40.5)28.9 (23.9 to 34.0)
Week 5246.2 (40.0 to 52.3)42.3 (36.4 to 48.3)35.4 (29.6 to 41.2)
Week 9651.4 (44.8 to 57.9)42.8 (36.6 to 49.0)42.2 (35.9 to 48.5)
SecondaryPercentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 16, 52, and 96
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 1639.3 (32.7 to 45.8)39.5 (33.2 to 45.9)33.3 (27.1 to 39.4)
Week 5249.5 (42.3 to 56.8)47.4 (40.5 to 54.4)42.3 (35.3 to 49.3)
Week 9652.3 (44.6 to 60.1)47.0 (39.7 to 54.2)49.1 (41.7 to 56.6)
SecondaryPercentage of Participants With a ≥3-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 16, 52, and 96
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥3-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 1612.7 (8.8 to 16.5)12.8 (9.0 to 16.6)10.3 (6.8 to 13.8)
Week 5217.0 (12.3 to 21.6)15.3 (10.9 to 19.8)14.2 (10.0 to 18.5)
Week 9622.4 (16.9 to 27.8)14.6 (10.0 to 19.1)20.9 (15.8 to 26.0)
SecondaryPercentage of Participants With a ≥3-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 16, 52, and 96
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥3-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 1614.4 (9.7 to 19.1)15.1 (10.4 to 19.8)10.4 (6.4 to 14.4)
Week 5219.5 (13.7 to 25.2)17.4 (12.1 to 22.8)16.4 (11.2 to 21.6)
Week 9623.9 (17.3 to 30.5)17.1 (11.5 to 22.6)25.3 (18.9 to 31.6)
SecondaryPercentage of Participants With a ≥4-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 16, 52, and 96
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥4-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 163.6 (1.4 to 5.8)3.5 (1.4 to 5.6)3.9 (1.7 to 6.2)
Week 525.8 (2.9 to 8.7)4.9 (2.2 to 7.7)4.5 (1.9 to 7.0)
Week 965.9 (2.8 to 9.0)5.8 (2.8 to 8.8)6.0 (3.0 to 9.0)
SecondaryPercentage of Participants With a ≥4-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 16, 52, and 96
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥4-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 163.9 (1.3 to 6.4)3.5 (1.1 to 5.9)3.6 (1.2 to 6.1)
Week 526.2 (2.7 to 9.7)5.1 (2.0 to 8.3)4.2 (1.4 to 7.0)
Week 967.0 (3.0 to 11.0)6.8 (3.1 to 10.5)6.3 (2.8 to 9.8)
SecondaryPercentage of Participants Without Proliferative Diabetic Retinopathy (PDR) at Baseline Who Developed New PDR at Week 52, ITT and Treatment-Naive Populations

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). PDR was defined as an ETDRS DRSS score of ≥61 on the 7-field/4-wide field color fundus photographs assessment by a central reading center. The weighted percentages of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% CI is a rounding of 95.04% CI.

Time frame:
Baseline and Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Without Proliferative Diabetic Retinopathy (PDR) at Baseline Who Developed New PDR at Week 52, ITT and Treatment-Naive Populations
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
ITT Population0.9 (0.0 to 2.2)0.9 (0.0 to 2.2)0.5 (0.0 to 1.4)
Treatment-Naive Population0.0 (0.0 to 0.0)1.2 (0.0 to 2.8)0.6 (0.0 to 1.9)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.4 · 95% CI -1.1 to 2.0
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.4 · 95% CI -1.1 to 2.0
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -0.6 · 95% CI -1.9 to 0.6
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.5 · 95% CI -1.5 to 2.5
SecondaryPercentage of Participants Without High-Risk Proliferative Diabetic Retinopathy (PDR) at Baseline Who Developed High-Risk PDR at Week 52, ITT and Treatment-Naive Populations

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced PDR. High-risk PDR was defined as an ETDRS DRSS score of ≥71 on the 7-field/4-wide field color fundus photographs assessment by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% CI is a rounding of 95.04% CI.

Time frame:
Baseline and Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Without High-Risk Proliferative Diabetic Retinopathy (PDR) at Baseline Who Developed High-Risk PDR at Week 52, ITT and Treatment-Naive Populations
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
ITT Population0.4 (0.0 to 1.2)0.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
Treatment-Naive Population0.0 (0.0 to 0.0)0.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.4 · 95% CI -0.4 to 1.2
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.0 · 95% CI 0.0 to 0.0
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.0 · 95% CI 0.0 to 0.0
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.0 · 95% CI 0.0 to 0.0
SecondaryPercentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 52, ITT Population
Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 52, ITT Population
Percentage of participantsB: Faricimab 6 mg PTI
Once Every 4 Weeks10.8 (7.2 to 14.4)
Once Every 8 Weeks15.4 (11.2 to 19.6)
Once Every 12 Weeks21.0 (16.3 to 25.7)
Once Every 16 Weeks52.8 (47.0 to 58.6)
SecondaryPercentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 52, Treatment-Naive Population
Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 52, Treatment-Naive Population
Percentage of participantsB: Faricimab 6 mg PTI
Once Every 4 Weeks9.0 (5.2 to 12.8)
Once Every 8 Weeks14.4 (9.8 to 19.0)
Once Every 12 Weeks22.1 (16.6 to 27.5)
Once Every 16 Weeks54.5 (47.9 to 61.1)
SecondaryPercentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 96, ITT Population
Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 96, ITT Population
Percentage of participantsB: Faricimab 6 mg PTI
Once Every 4 Weeks7.0 (4.0 to 10.1)
Once Every 8 Weeks14.8 (10.6 to 19.1)
Once Every 12 Weeks18.1 (13.5 to 22.8)
Once Every 16 Weeks60.0 (54.1 to 65.9)
SecondaryPercentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 96, Treatment-Naive Population
Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 96, Treatment-Naive Population
Percentage of participantsB: Faricimab 6 mg PTI
Once Every 4 Weeks7.2 (3.7 to 10.7)
Once Every 8 Weeks11.1 (6.8 to 15.3)
Once Every 12 Weeks16.8 (11.7 to 21.9)
Once Every 16 Weeks64.9 (58.4 to 71.4)
SecondaryPercentage of Participants in the Faricimab 6 mg PTI Arm at Week 52 Who Achieved a Once Every 12-Weeks or 16-Weeks Treatment Interval Without an Interval Decrease Below Once Every 12 Weeks, ITT and Treatment-Naive Populations
Time frame:
From start of PTI (Week 12 or later) until Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants in the Faricimab 6 mg PTI Arm at Week 52 Who Achieved a Once Every 12-Weeks or 16-Weeks Treatment Interval Without an Interval Decrease Below Once Every 12 Weeks, ITT and Treatment-Naive Populations
Percentage of participantsB: Faricimab 6 mg PTI
ITT Population67.8 (62.4 to 73.3)
Treatment-Naive Population71.6 (65.7 to 77.6)
SecondaryPercentage of Participants in the Faricimab 6 mg PTI Arm at Week 96 Who Achieved a Once Every 12-Weeks or 16-Weeks Treatment Interval Without an Interval Decrease Below Once Every 12 Weeks, ITT and Treatment-Naive Populations
Time frame:
From start of PTI (Week 12 or later) until Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants in the Faricimab 6 mg PTI Arm at Week 96 Who Achieved a Once Every 12-Weeks or 16-Weeks Treatment Interval Without an Interval Decrease Below Once Every 12 Weeks, ITT and Treatment-Naive Populations
Percentage of participantsB: Faricimab 6 mg PTI
ITT Population60.4 (54.5 to 66.2)
Treatment-Naive Population64.4 (57.9 to 70.9)
SecondaryChange From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment (U.S. and Canada vs. the rest of the world; Asia and rest of the world regions were combined). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
From Baseline through Week 56
Reported as:
Mean · microns
Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations
micronsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
ITT Population-206.6 (-214.7 to -198.4)-196.5 (-204.7 to -188.4)-170.3 (-178.5 to -162.2)
Treatment-Naive Population-204.6 (-213.5 to -195.7)-197.5 (-206.2 to -188.8)-173.6 (-182.3 to -164.8)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Adjusted mean difference: -36.2 · 95% CI -47.8 to -24.7
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Adjusted mean difference: -26.2 · 95% CI -37.7 to -14.7
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Adjusted mean difference: -31.1 · 95% CI -43.6 to -18.6
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Adjusted mean difference: -23.9 · 95% CI -36.2 to -11.6
SecondaryChange From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population

Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment (U.S. and Canada vs. the rest of the world; Asia and rest of the world regions were combined). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Mean · microns
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population
micronsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 4-118.4 (-128.5 to -108.2)-124.9 (-135.0 to -114.8)-111.0 (-121.2 to -100.8)
Week 8-145.9 (-155.2 to -136.5)-149.6 (-159.0 to -140.3)-130.9 (-140.4 to -121.5)
Week 12-165.6 (-174.3 to -156.9)-168.4 (-177.1 to -159.8)-144.7 (-153.4 to -136.0)
Week 16-177.6 (-186.0 to -169.2)-182.1 (-190.4 to -173.7)-152.7 (-161.1 to -144.3)
Week 20-184.6 (-193.2 to -176.1)-174.6 (-183.1 to -166.0)-159.0 (-167.6 to -150.4)
Week 24-196.4 (-204.8 to -188.0)-192.8 (-201.2 to -184.3)-146.3 (-154.7 to -137.8)
Week 28-174.6 (-184.4 to -164.9)-193.7 (-203.4 to -184.0)-163.8 (-173.6 to -154.0)
Week 32-200.2 (-209.4 to -191.0)-181.6 (-190.8 to -172.4)-147.2 (-156.4 to -138.0)
Week 36-179.4 (-188.9 to -169.8)-201.0 (-210.6 to -191.5)-166.0 (-175.7 to -156.4)
Week 40-205.1 (-214.5 to -195.7)-193.5 (-203.0 to -184.1)-153.9 (-163.4 to -144.4)
Week 44-187.5 (-197.4 to -177.5)-189.2 (-199.1 to -179.3)-172.6 (-182.6 to -162.6)
Week 48-209.7 (-218.6 to -200.8)-194.8 (-203.7 to -185.8)-163.2 (-172.2 to -154.3)
Week 52-191.0 (-200.6 to -181.4)-193.0 (-202.6 to -183.4)-179.2 (-188.9 to -169.5)
Week 56-212.4 (-221.5 to -203.4)-200.3 (-209.3 to -191.2)-164.4 (-173.5 to -155.2)
Week 60-197.8 (-207.4 to -188.2)-196.3 (-205.9 to -186.6)-182.0 (-191.7 to -172.3)
Week 64-214.9 (-224.0 to -205.9)-199.9 (-208.9 to -190.8)-171.5 (-180.6 to -162.4)
Week 68-201.1 (-210.0 to -192.3)-200.9 (-209.7 to -192.1)-186.8 (-195.7 to -177.9)
Week 72-216.2 (-224.9 to -207.6)-201.6 (-210.3 to -193.0)-182.3 (-191.1 to -173.6)
Week 76-206.0 (-215.1 to -197.0)-200.7 (-209.8 to -191.7)-188.4 (-197.6 to -179.3)
Week 80-219.1 (-227.7 to -210.5)-203.2 (-211.7 to -194.6)-184.5 (-193.2 to -175.9)
Week 84-211.8 (-221.1 to -202.5)-204.9 (-214.1 to -195.7)-186.2 (-195.5 to -176.9)
Week 88-218.6 (-228.0 to -209.3)-204.1 (-213.4 to -194.8)-183.7 (-193.1 to -174.3)
Week 92-210.9 (-220.1 to -201.7)-202.4 (-211.4 to -193.3)-193.9 (-203.2 to -184.7)
Week 96-224.0 (-232.9 to -215.1)-203.8 (-212.6 to -195.1)-194.7 (-203.6 to -185.8)
Week 100-213.1 (-221.8 to -204.3)-207.3 (-216.0 to -198.6)-200.2 (-209.0 to -191.4)
SecondaryChange From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population

Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (\<64 vs. ≥64 letters), and region of enrollment (U.S. and Canada vs. the rest of the world; Asia and rest of the world regions were combined). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Mean · microns
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population
micronsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 4-116.1 (-127.0 to -105.2)-121.5 (-132.1 to -110.9)-110.1 (-120.9 to -99.3)
Week 8-142.9 (-153.0 to -132.8)-147.4 (-157.3 to -137.5)-131.5 (-141.5 to -121.5)
Week 12-162.8 (-171.9 to -153.6)-166.7 (-175.7 to -157.8)-147.4 (-156.4 to -138.3)
Week 16-175.1 (-183.8 to -166.3)-181.7 (-190.3 to -173.1)-155.9 (-164.5 to -147.2)
Week 20-182.9 (-192.0 to -173.8)-178.1 (-187.0 to -169.2)-161.6 (-170.6 to -152.6)
Week 24-194.2 (-203.4 to -184.9)-191.1 (-200.2 to -182.0)-149.7 (-158.9 to -140.6)
Week 28-177.4 (-188.1 to -166.7)-194.0 (-204.4 to -183.5)-167.5 (-178.0 to -156.9)
Week 32-196.4 (-206.6 to -186.2)-183.7 (-193.7 to -173.8)-150.2 (-160.3 to -140.2)
Week 36-181.9 (-191.9 to -171.9)-203.6 (-213.3 to -193.8)-168.7 (-178.6 to -158.9)
Week 40-198.9 (-209.7 to -188.1)-192.1 (-202.8 to -181.4)-157.4 (-168.2 to -146.5)
Week 44-187.3 (-198.5 to -176.1)-189.3 (-200.2 to -178.3)-172.9 (-184.0 to -161.8)
Week 48-207.3 (-217.3 to -197.3)-194.9 (-204.7 to -185.1)-165.0 (-174.9 to -155.1)
Week 52-191.1 (-201.7 to -180.5)-196.2 (-206.5 to -185.9)-181.1 (-191.6 to -170.5)
Week 56-210.4 (-220.0 to -200.8)-200.9 (-210.3 to -191.5)-171.0 (-180.6 to -161.4)
Week 60-195.0 (-205.6 to -184.4)-198.0 (-208.4 to -187.5)-185.1 (-195.6 to -174.5)
Week 64-213.7 (-223.5 to -203.9)-199.2 (-208.8 to -189.6)-175.3 (-184.9 to -165.6)
Week 68-201.5 (-211.2 to -191.7)-201.7 (-211.2 to -192.1)-189.1 (-198.8 to -179.5)
Week 72-215.9 (-225.5 to -206.4)-203.2 (-212.5 to -193.9)-184.1 (-193.5 to -174.6)
Week 76-204.8 (-214.8 to -194.9)-202.1 (-211.8 to -192.4)-189.8 (-199.7 to -180.0)
Week 80-217.3 (-227.0 to -207.5)-202.2 (-211.6 to -192.7)-186.2 (-195.9 to -176.6)
Week 84-211.0 (-221.6 to -200.4)-202.9 (-213.2 to -192.7)-185.7 (-196.1 to -175.2)
Week 88-215.9 (-226.4 to -205.5)-205.2 (-215.3 to -195.0)-186.4 (-196.7 to -176.1)
Week 92-208.8 (-218.9 to -198.7)-202.2 (-212.0 to -192.5)-195.9 (-205.9 to -186.0)
Week 96-221.0 (-231.4 to -210.7)-199.0 (-209.0 to -189.1)-196.7 (-206.9 to -186.6)
Week 100-213.4 (-222.7 to -204.1)-206.7 (-215.7 to -197.7)-201.3 (-210.5 to -192.1)
SecondaryPercentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

Absence of diabetic macular edema was defined as achieving a central subfield thickness (CST) of \<325 microns in the study eye. CST was defined as the distance between the internal limiting membrane and Bruch's membrane. For each participant, an average CST value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Average of Weeks 48, 52, and 56
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
ITT Population81.3 (76.8 to 85.9)78.0 (73.1 to 82.8)65.4 (59.9 to 70.8)
Treatment-Naive Population83.5 (78.4 to 88.5)80.4 (75.1 to 85.7)68.3 (62.1 to 74.4)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 16.0 · 95% CI 8.9 to 23.1
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 12.7 · 95% CI 5.4 to 20.0
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 15.2 · 95% CI 7.3 to 23.2
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 12.5 · 95% CI 4.4 to 20.6
SecondaryPercentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population

Absence of diabetic macular edema was defined as achieving a central subfield thickness of \<325 microns in the study eye. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 436.1 (30.8 to 41.4)41.3 (35.9 to 46.8)35.0 (29.7 to 40.4)
Week 848.4 (42.9 to 54.0)52.7 (47.2 to 58.2)42.6 (37.1 to 48.2)
Week 1260.9 (55.4 to 66.4)67.4 (62.1 to 72.6)49.6 (44.0 to 55.2)
Week 1667.2 (61.8 to 72.5)72.0 (66.9 to 77.0)58.6 (53.1 to 64.1)
Week 2071.1 (65.9 to 76.2)70.7 (65.6 to 75.8)58.9 (53.4 to 64.5)
Week 2476.5 (71.7 to 81.4)81.3 (76.8 to 85.8)53.7 (48.1 to 59.4)
Week 2871.4 (66.2 to 76.5)79.3 (74.6 to 84.0)62.5 (57.0 to 68.0)
Week 3279.0 (74.2 to 83.8)72.1 (66.8 to 77.4)55.8 (50.1 to 61.5)
Week 3670.9 (65.6 to 76.1)81.7 (77.1 to 86.3)63.1 (57.4 to 68.8)
Week 4082.3 (77.9 to 86.7)80.8 (76.1 to 85.5)58.8 (53.0 to 64.7)
Week 4474.7 (69.6 to 79.9)79.0 (74.3 to 83.8)67.6 (62.1 to 73.1)
Week 4886.5 (82.5 to 90.5)81.5 (76.8 to 86.1)64.0 (58.3 to 69.7)
Week 5277.4 (72.4 to 82.4)78.3 (73.4 to 83.1)71.1 (65.6 to 76.7)
Week 5686.5 (82.4 to 90.7)81.3 (76.6 to 86.0)65.0 (59.2 to 70.8)
Week 6078.8 (74.0 to 83.6)79.4 (74.6 to 84.3)72.3 (66.9 to 77.7)
Week 6488.3 (84.4 to 92.2)80.0 (75.2 to 84.8)67.7 (62.1 to 73.3)
Week 6883.5 (79.0 to 88.1)84.1 (79.7 to 88.5)74.8 (69.4 to 80.1)
Week 7288.0 (84.0 to 92.0)85.2 (81.0 to 89.5)70.2 (64.5 to 75.9)
Week 7685.6 (81.3 to 89.8)84.9 (80.5 to 89.2)76.0 (70.7 to 81.2)
Week 8088.5 (84.5 to 92.4)81.9 (77.3 to 86.6)73.2 (67.7 to 78.7)
Week 8485.1 (80.7 to 89.5)86.1 (82.0 to 90.3)74.9 (69.5 to 80.3)
Week 8890.4 (86.8 to 94.0)83.2 (78.7 to 87.7)74.2 (68.7 to 79.6)
Week 9286.5 (82.3 to 90.7)78.2 (73.2 to 83.3)78.2 (73.1 to 83.3)
Week 9691.8 (88.4 to 95.3)83.7 (79.2 to 88.2)77.3 (72.1 to 82.4)
Week 10089.5 (85.7 to 93.4)85.9 (81.7 to 90.1)81.0 (76.1 to 86.0)
SecondaryPercentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population

Retinal dryness was defined as achieving a central subfield thickness (ILM-BM) of \<280 microns. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted estimates of the percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 415.4 (11.5 to 19.4)16.0 (12.0 to 19.9)12.6 (8.9 to 16.3)
Week 824.2 (19.6 to 28.8)24.6 (19.9 to 29.3)16.2 (12.1 to 20.3)
Week 1232.4 (27.3 to 37.5)34.1 (28.9 to 39.4)22.1 (17.4 to 26.7)
Week 1638.4 (33.0 to 43.9)42.5 (36.9 to 48.0)23.2 (18.5 to 27.9)
Week 2045.9 (40.3 to 51.5)40.6 (35.0 to 46.1)29.7 (24.5 to 34.8)
Week 2453.0 (47.3 to 58.7)48.1 (42.4 to 53.8)26.6 (21.6 to 31.6)
Week 2845.9 (40.1 to 51.7)50.2 (44.4 to 55.9)34.3 (28.8 to 39.8)
Week 3255.0 (49.1 to 60.8)43.2 (37.3 to 49.0)30.6 (25.1 to 36.1)
Week 3648.5 (42.5 to 54.5)54.3 (48.4 to 60.3)39.2 (33.4 to 45.1)
Week 4057.5 (51.8 to 63.2)51.3 (45.3 to 57.3)32.2 (26.7 to 37.7)
Week 4451.5 (45.7 to 57.4)51.9 (46.1 to 57.8)37.1 (31.4 to 42.8)
Week 4863.2 (57.4 to 69.0)50.1 (44.2 to 56.0)36.2 (30.4 to 42.0)
Week 5257.8 (51.9 to 63.7)54.7 (48.7 to 60.6)42.3 (36.2 to 48.4)
Week 5666.3 (60.6 to 72.0)56.9 (51.0 to 62.9)41.2 (35.1 to 47.2)
Week 6060.2 (54.4 to 66.0)54.0 (48.0 to 60.0)47.7 (41.6 to 53.7)
Week 6468.5 (62.8 to 74.1)55.4 (49.4 to 61.3)47.4 (41.3 to 53.4)
Week 6861.3 (55.3 to 67.3)57.7 (51.7 to 63.8)52.3 (46.1 to 58.5)
Week 7265.8 (60.1 to 71.5)58.5 (52.6 to 64.3)47.7 (41.4 to 53.9)
Week 7665.9 (60.1 to 71.8)54.8 (48.6 to 60.9)53.9 (47.7 to 60.1)
Week 8070.1 (64.5 to 75.8)54.7 (48.7 to 60.6)51.1 (44.8 to 57.3)
Week 8467.1 (61.3 to 72.9)61.2 (55.5 to 67.0)56.0 (49.9 to 62.2)
Week 8872.2 (66.7 to 77.7)58.0 (52.1 to 64.0)54.2 (48.0 to 60.5)
Week 9266.2 (60.5 to 72.0)58.0 (52.2 to 63.8)57.9 (51.7 to 64.0)
Week 9672.7 (67.2 to 78.2)61.4 (55.6 to 67.2)58.0 (51.8 to 64.2)
Week 10071.4 (65.9 to 76.8)60.5 (54.5 to 66.4)60.7 (54.5 to 66.8)
SecondaryPercentage of Participants With Absence of Intraretinal Fluid in the Study Eye Over Time, ITT Population

Intraretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world); Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 16, 48, 52, 56, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 1616.3 (12.0 to 20.5)21.9 (17.1 to 26.6)13.4 (9.6 to 17.3)
Week 4845.6 (39.7 to 51.6)33.2 (27.5 to 38.9)21.9 (17.0 to 26.9)
Week 5242.1 (36.3 to 47.9)38.8 (32.9 to 44.7)25.5 (20.2 to 30.8)
Week 5649.3 (43.3 to 55.3)42.7 (36.7 to 48.7)23.7 (18.5 to 28.9)
Week 9258.5 (52.3 to 64.7)43.2 (37.1 to 49.3)33.2 (27.4 to 39.1)
Week 9663.1 (57.0 to 69.2)47.6 (41.5 to 53.7)34.6 (28.7 to 40.6)
Week 10061.4 (55.2 to 67.5)44.5 (38.4 to 50.7)37.6 (31.5 to 43.6)
SecondaryPercentage of Participants With Absence of Subretinal Fluid in the Study Eye Over Time, ITT Population

Subretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world); Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 16, 48, 52, 56, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Subretinal Fluid in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 1695.3 (92.9 to 97.7)94.5 (92.0 to 97.1)95.9 (93.7 to 98.2)
Week 4897.0 (95.0 to 99.0)95.5 (93.1 to 97.9)96.2 (93.8 to 98.5)
Week 5295.8 (93.3 to 98.2)95.4 (92.9 to 97.9)98.0 (96.2 to 99.7)
Week 5697.0 (95.0 to 99.0)97.0 (95.0 to 99.0)97.3 (95.3 to 99.3)
Week 9294.8 (92.1 to 97.6)94.5 (91.7 to 97.3)96.7 (94.5 to 99.0)
Week 9697.0 (94.8 to 99.1)94.1 (91.3 to 97.0)96.7 (94.5 to 98.9)
Week 10094.3 (91.4 to 97.2)97.3 (95.4 to 99.2)97.1 (95.0 to 99.2)
SecondaryPercentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time, ITT Population

Intraretinal fluid and subretinal fluid were measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world); Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 16, 48, 52, 56, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 1615.9 (11.7 to 20.1)21.9 (17.1 to 26.6)13.1 (9.3 to 16.9)
Week 4845.2 (39.3 to 51.2)32.4 (26.8 to 38.1)21.9 (17.0 to 26.9)
Week 5242.1 (36.3 to 47.9)38.0 (32.2 to 43.8)25.5 (20.2 to 30.8)
Week 5647.0 (41.0 to 53.0)42.4 (36.4 to 48.3)23.7 (18.5 to 28.9)
Week 9257.2 (51.0 to 63.4)41.3 (35.2 to 47.3)32.0 (26.3 to 37.8)
Week 9662.4 (56.2 to 68.5)46.0 (39.8 to 52.1)34.2 (28.3 to 40.1)
Week 10059.3 (53.0 to 65.5)43.8 (37.6 to 49.9)37.4 (31.4 to 43.5)
SecondaryChange From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Composite Score Over Time, ITT Population

The NEI VFQ-25 captures a patient's perception of vision-related functioning and quality of life. The core measure includes 25 items that comprise 11 vision-related subscales and one item on general health. The composite score ranges from 0 to 100, with higher scores, or a positive change from baseline, indicating better vision-related functioning. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline NEI VFQ-25 Composite Score (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% CI is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 24, 52, and 100
Reported as:
Mean · score on a scale
Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Composite Score Over Time, ITT Population
score on a scaleA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 246.0 (4.8 to 7.2)6.9 (5.7 to 8.1)6.0 (4.8 to 7.2)
Week 527.3 (5.9 to 8.6)7.9 (6.6 to 9.3)7.5 (6.1 to 8.9)
Week 1008.0 (6.6 to 9.4)7.4 (6.0 to 8.8)7.6 (6.1 to 9.0)
SecondaryPercentage of Participants With at Least One Adverse Event

This analysis of adverse events (AEs) includes both ocular and non-ocular (systemic) AEs. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. AEs of special interest included the following: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law; Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation.

Time frame:
From first dose of study drug through end of study (up to 2 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Adverse Event
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Adverse Event (AE)92.791.489.1
Serious AE (SAE)35.537.429.9
AE Leading to Withdrawal from Study Treatment2.62.91.6
AE of Special Interest (AESI)6.17.04.8
SecondaryPercentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye

This analysis of adverse events (AEs) only includes ocular AEs, which are categorized as having occurred either in the study eye or the fellow eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation.

Time frame:
From first dose of study drug through end of study (up to 2 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Study Eye: Adverse Event (AE)47.046.646.3
Study Eye: Serious AE (SAE)3.84.52.3
Study Eye: AE Leading to Withdrawal from Treatment1.31.90.3
Study Eye: Treatment-related AE3.22.21.9
Study Eye: Treatment-related SAE0.01.30.0
Study Eye: AE of Special Interest (AESI)3.54.22.6
Study Eye: AESI, Drop in VA Score ≥30 Letters2.62.22.3
Study Eye: AESI, Associated with Severe IOI0.61.60.0
Study Eye: AESI, Intervention Req. to Prevent Permanent Vision Loss1.01.30.3
Fellow Eye: AE40.342.246.3
Fellow Eye: SAE2.93.52.3
Fellow Eye: AESI2.92.92.3
Fellow Eye: AESI, Drop in VA Score ≥30 Letters2.21.91.3
Fellow Eye: AESI, Associated with Severe IOI0.00.30.0
Fellow Eye: AESI, Intervention Req. to Prevent Permanent Vision Loss1.01.31.0
SecondaryPercentage of Participants With at Least One Non-Ocular Adverse Event

This analysis of adverse events (AEs) only includes non-ocular (systemic) AEs. Investigators sought information on adverse events (AEs) at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. The non-ocular AE of special interest was: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

Time frame:
From first dose of study drug through end of study (up to 2 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Non-Ocular Adverse Event
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Adverse Event (AE)76.780.277.8
Serious AE (SAE)31.631.027.0
AE Leading to Withdrawal from Study Treatment1.31.01.3
AE of Special Interest (AESI)0.00.00.3
AESI, Elevated ALT or AST with Either Elevated Bilirubin or Clinical Jaundice0.00.00.3
SecondaryPlasma Concentration of Faricimab Over Time

Faricimab concentration in plasma was determined using a validated immunoassay method.

Time frame:
Pre-dose on Day 1 (Baseline); Weeks 4, 28, 52, 76, and 100
Reported as:
Mean · micrograms per millilitre (μg/mL)
Plasma Concentration of Faricimab Over Time
micrograms per millilitre (μg/mL)A: Faricimab 6 mg Q8WB: Faricimab 6 mg PTI
Baseline0.0000 ± 0.00010.0000 ± 0.0001
Week 40.0211 ± 0.03370.0181 ± 0.0139
Week 280.0033 ± 0.00530.0089 ± 0.0145
Week 520.0052 ± 0.01040.0100 ± 0.0132
Week 760.0048 ± 0.00850.0068 ± 0.0255
Week 1000.0052 ± 0.00870.0077 ± 0.0126
SecondaryPercentage of Participants Who Test Positive for Treatment-Emergent Anti-Drug Antibodies Against Faricimab During the Study

Anti-drug antibodies (ADAs) against fariciamb were detected in plasma using a validated bridging enzyme-linked immunosorbent assay (ELISA). The percentage of participants with treatment-emergent ADA-positive samples includes post-baseline evaluable participants with at least one treatment-induced (defined as having an ADA-negative sample or missing sample at baseline and any positive post-baseline sample) or treatment-boosted (defined as having an ADA-positive sample at baseline and any positive post-baseline sample with a titer that is equal to or greater than 4-fold baseline titer) ADA-positive sample during the study treatment period.

Time frame:
Baseline, Weeks 4, 28, 52, 76, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Who Test Positive for Treatment-Emergent Anti-Drug Antibodies Against Faricimab During the Study
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTI
Total Treatment-Emergent ADA-Positive12.610.6
Treatment-Induced ADA-Positive12.610.3
Treatment-Boosted ADA-Positive0.00.3

Adverse events

Collected over From Baseline until Week 100. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
A: Faricimab 6 mg Q8W16/313 (5.1%)111/313 (35.5%)161/313 (51.4%)
B: Faricimab 6 mg PTI21/313 (6.7%)117/313 (37.4%)163/313 (52.1%)
C: Aflibercept 2 mg Q8W13/311 (4.2%)93/311 (29.9%)163/311 (52.4%)
Most frequent serious events
Showing 10 of 264
Most frequent serious events
EventA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
COVID-19Infections and infestations5/31310/3134/311
PneumoniaInfections and infestations8/3134/3137/311
OsteomyelitisInfections and infestations3/3131/3137/311
SepsisInfections and infestations6/3130/3137/311
Cardiac failure congestiveCardiac disorders7/3133/3135/311
Myocardial infarctionCardiac disorders2/3135/3135/311
Acute myocardial infarctionCardiac disorders5/3133/3134/311
Coronary artery diseaseCardiac disorders2/3135/3134/311
DeathGeneral disorders3/3135/3131/311
CellulitisInfections and infestations4/3135/3134/311
Most frequent other events
Most frequent other events
EventA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
CataractEye disorders58/31347/31355/311
HypertensionVascular disorders22/31332/31336/311
Diabetic retinal oedemaEye disorders20/31329/31333/311
Conjunctival haemorrhageEye disorders25/31333/31324/311
NasopharyngitisInfections and infestations27/31318/31330/311
Vitreous detachmentEye disorders20/31323/31313/311
Urinary tract infectionInfections and infestations14/31315/31319/311
FallInjury, poisoning and procedural complications16/31319/3139/311
Vitreous floatersEye disorders17/31311/31310/311
Intraocular pressure increasedInvestigations17/31313/31311/311

Baseline characteristics

The overall number of baseline participants (940) comprises the Intent-to-Treat (ITT) Population, which includes all global participants who were randomized in the study, grouped according to the treatment assigned at randomization.

Age, Continuous
Age, Continuous(Years)A: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8WTotal
ITT Population61.6 ± 9.562.8 ± 10.062.2 ± 9.662.2 ± 9.7
Treatment-Naive Population61.0 ± 9.662.5 ± 10.362.2 ± 9.961.9 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)A: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8WTotal
ITT Population — Female128116134378
ITT Population — Male187197178562
Treatment-Naive Population — Female9391108292
Treatment-Naive Population — Male145154134433
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)A: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8WTotal
ITT Population — Hispanic or Latino374037114
ITT Population — Not Hispanic or Latino273268272813
ITT Population — Unknown or Not Reported55313
Treatment-Naive Population — Hispanic or Latino31323194
Treatment-Naive Population — Not Hispanic or Latino202210208620
Treatment-Naive Population — Unknown or Not Reported53311
Race (NIH/OMB)
Race (NIH/OMB)(Participants)A: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8WTotal
ITT Population — American Indian or Alaska Native65718
ITT Population — Asian31262784
ITT Population — Native Hawaiian or Other Pacific Islander2035
ITT Population — Black or African American22251259
ITT Population — White241240253734
ITT Population — More than one race0101
ITT Population — Unknown or Not Reported13161039
Treatment-Naive Population — American Indian or Alaska Native43613
Treatment-Naive Population — Asian21182059
Treatment-Naive Population — Native Hawaiian or Other Pacific Islander2024
Treatment-Naive Population — Black or African American1724950
Treatment-Naive Population — White181186196563
Treatment-Naive Population — More than one race0101
Treatment-Naive Population — Unknown or Not Reported1313935
Number of Participants by Previous Treatment Status with Intravitreal Anti-VEGF Agents
Number of Participants by Previous Treatment Status with Intravitreal Anti-VEGF Agents(Participants)A: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8WTotal
Treatment-Naive238245242725
Previously Treated776870215
Region of Enrollment
Region of Enrollment(Participants)A: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8WTotal
ITT Population — United States and Canada167168168503
ITT Population — Asia21192060
ITT Population — Rest of the World127126124377
Treatment-Naive Population — United States and Canada130134135399
Treatment-Naive Population — Asia14141543
Treatment-Naive Population — Rest of the World949792283
Number of Participants by the Eye Chosen as the Study Eye (Left or Right)
Number of Participants by the Eye Chosen as the Study Eye (Left or Right)(Participants)A: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8WTotal
ITT Population — Left Eye150172151473
ITT Population — Right Eye165141161467
Treatment-Naive Population — Left Eye117130117364
Treatment-Naive Population — Right Eye121115125361
Baseline Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye
Baseline Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye(ETDRS Letters)A: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8WTotal
ITT Population62.0 ± 9.961.9 ± 10.262.2 ± 9.562.0 ± 9.9
Treatment-Naive Population62.3 ± 9.961.8 ± 10.762.6 ± 9.262.2 ± 9.9

3 further baseline measures are reported on the registry.

08

Study locations

185 sites
  • Barnet Dulaney Perkins Eye Center
    Mesa, Arizona 85206, United States
  • Arizona Retina and Vitreous Consultants
    Phoenix, Arizona 85021, United States
  • Retina Associates Southwest PC
    Tucson, Arizona 85704, United States
  • Retinal Diagnostic Center
    Campbell, California 95008, United States
  • Eye Medical Center
    Fresno, California 93720, United States
  • East Bay Retina Consultants
    Oakland, California 94609, United States
  • Southern CA Desert Retina Cons
    Palm Desert, California 92211, United States
  • California Eye Specialists Medical group Inc.
    Pasadena, California 91107, United States
  • Retina Consultants, San Diego
    Poway, California 92064, United States
  • Retina Consultants of Southern California
    Redlands, California 92373, United States
  • Kaiser Permanente Riverside Medical Center
    Riverside, California 92505, United States
  • University of California, Davis, Eye Center
    Sacramento, California 95817, United States
  • W Coast Retina Med Group Inc
    San Francisco, California 94107, United States
  • Orange County Retina Med Group
    Santa Ana, California 92705, United States
  • Colorado Retina Associates, PC
    Lakewood, Colorado 80228, United States
  • Rand Eye
    Deerfield Beach, Florida 33064, United States
  • Retina Care Specialists
    Palm Beach Gardens, Florida 33410, United States
  • Retina Specialty Institute
    Pensacola, Florida 32503, United States
  • Southern Vitreoretinal Assoc
    Tallahassee, Florida 32308, United States
  • Retina Associates of Florida, LLC
    Tampa, Florida 33609, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Georgia Retina PC
    Marietta, Georgia 30060, United States
  • Retina Consultants of Hawaii
    ‘Aiea, Hawaii 96701, United States
  • Midwest Eye Institute
    Indianapolis, Indiana 46290, United States
  • Wolfe Eye Clinic
    West Des Moines, Iowa 50266, United States
  • Retina Associates
    Lenexa, Kansas 66215, United States
  • Vitreo-Retinal Consultants
    Wichita, Kansas 67214, United States
  • Retina Associates of Kentucky
    Lexington, Kentucky 40509, United States
  • Paducah Retinal Center
    Paducah, Kentucky 42001, United States
  • Maine Eye Center
    Portland, Maine 04101, United States
  • The Retina Care Center
    Baltimore, Maryland 21209, United States
  • Johns Hopkins Med; Wilmer Eye Inst
    Baltimore, Maryland 21287, United States
  • Retina Group of Washington
    Chevy Chase, Maryland 20815, United States
  • Cumberland Valley Retina PC
    Hagerstown, Maryland 21740, United States
  • Ophthalmic Consultants of Boston
    Boston, Massachusetts 02114, United States
  • Beetham Eye Institute, Joslin Diabetes Center
    Boston, Massachusetts 02215, United States
  • Vitreo-Retinal Associates, PC
    Worcester, Massachusetts 01605, United States
  • Foundation for Vision Research
    Grand Rapids, Michigan 49546, United States
  • Assoc Retinal Consultants PC
    Royal Oak, Michigan 48073, United States
  • Associated Retinal Consultants, P.C.
    Traverse City, Michigan 49686, United States
  • Vitreoretinal Surgery
    Edina, Minnesota 55435, United States
  • Midwest Vision Research Foundation
    Chesterfield, Missouri 63017, United States
  • Sierra Eye Associates
    Reno, Nevada 89502, United States
  • Mid Atlantic Retina - Wills Eye Hospital
    Cherry Hill, New Jersey 08034, United States
  • NJ Retina
    Edison, New Jersey 08820, United States
  • Retinal & Ophthalmic Cons PC
    Northfield, New Jersey 08225, United States
  • Retina Associates of NJ
    Teaneck, New Jersey 07666, United States
  • University of New Mexico
    Albuquerque, New Mexico 87131, United States
  • Capital Region Retina
    Albany, New York 12206, United States
  • Long Is. Vitreoretinal Consult
    Great Neck, New York 11021, United States
  • Retina Vit Surgeons/Central NY
    Liverpool, New York 13088, United States
  • MaculaCare, PLLC
    New York, New York 10021, United States
  • Island Retina
    Shirley, New York 11967, United States
  • Western Carolina Retinal Associate PA
    Asheville, North Carolina 28803, United States
  • Char Eye Ear &Throat Assoc
    Charlotte, North Carolina 28210, United States
  • Graystone Eye
    Hickory, North Carolina 28602, United States
  • Carolina Eye Associates
    Southern Pines, North Carolina 28387, United States
  • Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Cincinnati Eye Institute
    Cincinnati, Ohio 45242, United States
  • Retina Assoc of Cleveland Inc
    Cleveland, Ohio 44122, United States
  • OSU Eye Physicians & Surgeons
    Columbus, Ohio 43212, United States
  • Midwest Retina
    Dublin, Ohio 43016, United States
  • Retina Vitreous Center
    Edmond, Oklahoma 73013, United States
  • Retina Northwest
    Portland, Oregon 97221, United States
  • Black Hills Eye Institute
    Rapid City, South Dakota 57701, United States
  • Charles Retina Institute
    Memphis, Tennessee 38119, United States
  • Retina Res Institute of Texas
    Abilene, Texas 79606, United States
  • Austin Clinical Research LLC
    Austin, Texas 78750, United States
  • Retina Consultants of Texas
    Bellaire, Texas 77401, United States
  • Texas Retina Associates
    Dallas, Texas 75231, United States
  • Retina Specialists
    DeSoto, Texas 75115, United States
  • Valley Retina Institute P.A.
    Harlingen, Texas 78550, United States
  • Retina & Vitreous of Texas
    Houston, Texas 77025, United States
  • Med Center Ophthalmology Assoc
    San Antonio, Texas 78240, United States
  • Eye Care Assoc of East Texas
    Tyler, Texas 75701, United States
  • Strategic Clinical Research Group, LLC
    Willow Park, Texas 76087, United States
  • Retina Associates of Utah
    Salt Lake City, Utah 84107, United States
  • University of Utah; Division of Gastroenterology/Hepatology
    Salt Lake City, Utah 84132, United States
  • University of Vermont Medical Center; Investigational Drug Service, Pharmacy Department/Baird 1
    Burlington, Vermont 05401, United States
  • Emerson Clinical Research Institute
    Falls Church, Virginia 22042, United States
  • Piedmont Eye Center
    Lynchburg, Virginia 24502, United States
  • Wagner Macula & Retina Center
    Norfolk, Virginia 23502, United States
  • Spokane Eye Clinical Research
    Spokane, Washington 99204, United States
  • West Virginia University Eye Institute
    Morgantown, West Virginia 26506, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
  • LKH-Univ.Klinikum Graz; Universitäts-Augenklinik
    Graz, 8036, Austria
  • Kepler Universitätskliniken GmbH - Med Campus III; Abt. für Augenheilkunde
    Linz, 4021, Austria
  • Medizinische Universität Wien; Universitätsklinik für Augenheilkunde und Optometrie
    Vienna, 1090, Austria
  • Hanusch Krankenhaus; Abteilung für Augenkrankheiten mit Augen-Tagesklinik
    Vienna, 1140, Austria
  • Medical Center for Eye Health - Focus Ltd
    Sofia, 1303, Bulgaria
  • Pentagram Eye Hospital (Medical Center "Pentagram")
    Sofia, 1309, Bulgaria
  • Spec. Ophth. Hospital for Active Treatment- Academic Pashev
    Sofia, 1517, Bulgaria
  • Specialized Hospital for Active Treatment of Eye Diseases Zora
    Sofia, 1784, Bulgaria
  • Ambulatory - Medical Center for Specialized Medical Assistance - "Eye Clinic Sveta Petka" Ltd
    Varna, 9002, Bulgaria
  • Hopital Pellegrin; Ophtalmologie
    Bordeaux, 33000, France
  • Pole Vision Val d'Ouest; Ophtalmologie
    Écully, 69130, France
  • Centre Paradis Monticelli; Ophtalmologie
    Marseille, 13008, France
  • CHU Nantes - Hôtel Dieu; Ophthalmology
    Nantes, 44093, France
  • Centre Odeon; Exploration Ophtalmologique
    Paris, 75006, France
  • Hopital Lariboisiere; Ophtalmologie
    Paris, 75010, France

Showing the first 100 of 185 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmology. 2024 Jun;131(6):708-723. doi: 10.1016/j.ophtha.2023.12.026. Epub 2023 Dec 28. PubMed 38158159 ↗
  • Sheth VS, Schlottmann P, Lai TYY, Abreu F, Chang A, Eter N, Gibson K, Hu AY, Korobelnik JF, Kotak A, Kotecha A, O'Leary OE, Pearce I, Sim DA, Sun JK, Tang Y, Khanani AM. Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results from the RHONE-X Extension Trial. Ophthalmology. 2026 May;133(5):599-612. doi: 10.1016/j.ophtha.2026.01.001. Epub 2026 Jan 12. PubMed 41534798 ↗
  • Jaffe GJ, Deak G, Gibson K, Khurana RN, Nudleman E, Ogura Y, Schmidt-Erfurth U, Wang T, Westenskow PD, Wong D, Yiu G, Willis JR. IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS. Retina. 2025 Nov 1;45(11):2003-2011. doi: 10.1097/IAE.0000000000004572. PubMed 40668667 ↗
  • Zarbin M, Tabano D, Ahmed A, Amador M, Ding A, Holekamp N, Lu XY, Stoilov I, Yang M. Efficacy of Faricimab versus Aflibercept in Diabetic Macular Edema in the 20/50 or Worse Vision Subgroup in Phase III YOSEMITE and RHINE Trials. Ophthalmology. 2024 Nov;131(11):1258-1270. doi: 10.1016/j.ophtha.2024.05.025. Epub 2024 Jun 8. PubMed 38852921 ↗
  • von Schulthess EL, Maunz A, Chakravarthy U, Holekamp N, Pauleikhoff D, Patel K, Bachmeier I, Yu S, Cohen Y, Scherb MP, Jones IL, Gibson K, Willis JR, Glittenberg C, Singh RP, Fauser S. Intraretinal Hyper-Reflective Foci Are Almost Universally Present and Co-Localize With Intraretinal Fluid in Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2024 May 1;65(5):26. doi: 10.1167/iovs.65.5.26. PubMed 38758639 ↗
  • Gamble A, Khan T, Hughes A, Guo Y, Vasaitis S, Bidwell J, Christman B. Telehealth Diabetes Prevention Program for Adults With Prediabetes in an Academic Medical Center Setting: Protocol for a Hybrid Type III Trial. JMIR Res Protoc. 2023 Nov 13;12:e50183. doi: 10.2196/50183. PubMed 37955955 ↗
  • Stockwell AD, Chang MC, Mahajan A, Forrest W, Anegondi N, Pendergrass RK, Selvaraj S, Reeder J, Wei E, Iglesias VA, Creps NM, Macri L, Neeranjan AN, van der Brug MP, Scales SJ, McCarthy MI, Yaspan BL. Multi-ancestry GWAS analysis identifies two novel loci associated with diabetic eye disease and highlights APOL1 as a high risk locus in patients with diabetic macular edema. PLoS Genet. 2023 Aug 16;19(8):e1010609. doi: 10.1371/journal.pgen.1010609. eCollection 2023 Aug. PubMed 37585454 ↗
  • Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. PubMed 36897413 ↗
  • Eter N, Singh RP, Abreu F, Asik K, Basu K, Baumal C, Chang A, Csaky KG, Haskova Z, Lin H, Ruiz CQ, Ruamviboonsuk P, Silverman D, Wykoff CC, Willis JR. YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale. Ophthalmol Sci. 2021 Dec 30;2(1):100111. doi: 10.1016/j.xops.2021.100111. eCollection 2022 Mar. PubMed 36246184 ↗
  • Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. PubMed 35085503 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Oct 2020, 25 months.

Results were first posted in Mar 2022, 1 year 5 months after primary completion. A results delay was requested in Sep 2021.

Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 25 months is close to that.

Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2018
First posted
Aug 9, 2018
StartActual
Sep 5, 2018
Primary completionActual
Oct 20, 2020
CompletionActual
Sep 3, 2021
Results delay requested
Sep 1, 2021
Results first posted
Mar 22, 2022
Last update
Jul 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03622580
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 9, 2018
Start date
Sep 5, 2018
Primary completion
Oct 20, 2020
Completion
Sep 3, 2021
Results posted
Mar 22, 2022
Last update
Jul 11, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Faricimab

Start the discussion